var title_f20_47_21232="PDR traction retinal detachment 2";
var content_f20_47_21232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph of extremely severe traction retinal detachment in proliferative diabetic retinopathy, with elevation and distortion of the macula due to overgrowth and contraction of neovascular proliferations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21232=[""].join("\n");
var outline_f20_47_21232=null;
var title_f20_47_21233="CT scan showing large renal pelvic stone";
var content_f20_47_21233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing large renal pelvic stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan without contrast shows a large calculus in the right renal pelvis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark D Aronson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21233=[""].join("\n");
var outline_f20_47_21233=null;
var title_f20_47_21234="Patient information: Familial adenomatous polyposis (The Basics)";
var content_f20_47_21234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83757\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\">",
"         Diagram of the colon and rectum",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"           Upper endoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/9/38034\">",
"         Patient information: Colectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/34/25123\">",
"         Patient information: Colon and rectal cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7541\">",
"         Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Familial adenomatous polyposis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/familial-adenomatous-polyposis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10195474\">",
"      <span class=\"h1\">",
"       What is familial adenomatous polyposis (FAP)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Familial adenomatous polyposis (called &ldquo;FAP&rdquo; here) is a disease that causes abnormal growths in the large intestine (also called the colon), rectum and other areas (",
"      <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"       figure 1",
"      </a>",
"      ). Doctors call these growths &ldquo;polyps.&rdquo; They are not cancer, but can turn into cancer.",
"     </p>",
"     <p>",
"      Most people with FAP have hundreds or thousands of polyps. This means they have a much higher risk of colon cancer than other people. Without treatment, almost all people who have FAP get colon cancer by age 45.",
"     </p>",
"     <p>",
"      FAP is caused by an abnormal gene that runs in families. People who have FAP usually start showing signs of it in their teens or 20s. But some people get it in childhood. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195489\">",
"      <span class=\"h1\">",
"       What are the symptoms of FAP?",
"      </span>",
"      &nbsp;&mdash;&nbsp;FAP might not cause any symptoms. If it does, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bright red blood in bowel movements",
"       </li>",
"       <li>",
"        Diarrhea &ndash; Runny, watery bowel movements",
"       </li>",
"       <li>",
"        Constipation &ndash; Trouble having bowel movements",
"       </li>",
"       <li>",
"        Belly cramps",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Bloating &ndash; Feeling like the belly is full all the time",
"       </li>",
"       <li>",
"        Tiredness",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If someone in your family has FAP, you might have regular tests to check for it. Your doctor or nurse might find it before you have symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195503\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and learn about any symptoms you have. You might also have the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A test called a &ldquo;colonoscopy&rdquo; &ndash; In this test, the doctor puts a tube and a tiny camera through your anus and into your colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). During the test, he or she can check for polyps and take samples of tissue for testing. Another doctor looks at the tissue under a microscope. It can show if you have FAP or a different condition.",
"       </li>",
"       <li>",
"        A test called a &ldquo;sigmoidoscopy&rdquo; &ndash; This test is very similar to a colonoscopy, but it only looks at the last part of the colon, close to the rectum.",
"       </li>",
"       <li>",
"        A test called an &ldquo;upper endoscopy&rdquo; &ndash; This test uses a tube and tiny camera to check the upper digestive system (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 3",
"        </a>",
"        ). The doctor can also take samples of tissue in this test.",
"       </li>",
"       <li>",
"        Genetic testing &ndash; This is a blood test to look for the abnormal gene that causes FAP. Before the test, you will talk with a genetic counselor. A genetic counselor is a person who can help you understand what having the gene could mean for you and your family.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might have these tests in a different order or more than once. For example, if someone in your family has FAP, you might have genetic testing to see if you have the abnormal gene. Or you might have a colonoscopy to look for polyps. If a genetic test shows you have FAP, you might have a colonoscopy and endoscopy. The tests can show your doctor how many polyps you have and where they are.",
"     </p>",
"     <p>",
"      If you have FAP, your doctor might do exams or tests to look for other types of cancer, such as thyroid cancer. That&rsquo;s because people with FAP have a higher risk of some other cancers.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195520\">",
"      <span class=\"h1\">",
"       How is FAP treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your situation. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to take out the colon &ndash; This is called a &ldquo;colectomy.&rdquo; It is the main treatment for FAP. Taking out the tissue with polyps lowers the risk of cancer.",
"       </li>",
"       <li>",
"        Medicine to slow down polyps &ndash; Such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40949?source=see_link\">",
"         celecoxib",
"        </a>",
"        (brand name: CeleBREX&reg;). Doctors can give this before or after a colectomy.",
"       </li>",
"       <li>",
"        Polyp removal &ndash; Some people have a milder form of FAP that causes fewer polyps. Sometimes, doctors can remove polyps during a colonoscopy or endoscopy instead of doing a colectomy. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will talk with you about the treatment most likely to prevent cancer in your situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195535\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"       Patient information: Colectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/47/21234?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83757 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21234=[""].join("\n");
var outline_f20_47_21234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195474\">",
"      What is familial adenomatous polyposis (FAP)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195489\">",
"      What are the symptoms of FAP?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195503\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195520\">",
"      How is FAP treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195535\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\">",
"      Diagram of the colon and rectum",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"        Upper endoscopy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21235="TEE bicuspid aortic valve";
var content_f20_47_21235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/80529/teebicav_conv.mp4?title=TEE+bicuspid+aortic+valve\" style=\"width:431px;height:322px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bicuspid aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram show an aortic valve that has only two leaflets. Both leaflets have a moderate amount of calcium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21235=[""].join("\n");
var outline_f20_47_21235=null;
var title_f20_47_21236="Post radiation atypia benign";
var content_f20_47_21236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Post-radiation atypia in benign prostatic epithelium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign epithelial cells in an irradiated prostate gland show degenerative atypia and a \"streaming\" appearance (arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21236=[""].join("\n");
var outline_f20_47_21236=null;
var title_f20_47_21237="Caspofungin: Pediatric drug information";
var content_f20_47_21237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Caspofungin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"    see \"Caspofungin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/3/3124?source=see_link\">",
"    see \"Caspofungin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cancidas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cancidas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Echinocandin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Caspofungin treatment duration should be based on patient status and clinical response. Empiric therapy should be given until neutropenia resolves. In neutropenic patients, continue treatment for at least 7 days after both signs and symptoms of infection and neutropenia resolve. In patients with positive cultures, continue treatment for at least 14 days after the last positive culture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily; dosing based on a pharmacokinetic study of 18 neonates including preterm neonates that showed similar serum concentrations to standard adult doses. Reported trough concentrations were slightly elevated and not correlated with increased adverse events (S&aacute;ez-Llorens, 2009). Limited data available, further studies needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"      see \"Caspofungin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Caspofungin treatment duration should be based on patient status and clinical response. Empiric therapy should be given until neutropenia resolves. In neutropenic patients, continue treatment for at least 7 days after both signs and symptoms of infection and neutropenia resolve. In patients with positive cultures, continue treatment for at least 14 days after the last positive culture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 1 to &lt;3 months: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily; dosing based on a pharmacokinetic study of 18 infants that showed similar serum concentrations to standard adult doses (50 mg/day). Reported trough concentrations were slightly elevated and not correlated with increased adverse events (S&aacute;ez-Llorens, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children 3 months to 17 years: Initial dose: 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on day 1, subsequent dosing: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily; may increase to 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily if clinical response inadequate (maximum dose: 70 mg). Patients receiving carbamazepine, dexamethasone, efavirenz, nevirapine, phenytoin, or rifampin (and possibly other enzyme inducers): Consider 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily (maximum: 70 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Loading dose: 70 mg on day 1, followed by 50 mg once daily thereafter; 70 mg daily dose has been administered and well tolerated in patients not clinically responding to the daily 50 mg dose; may need to adjust dose in patients receiving a concomitant enzyme inducer. Doses greater than the standard adult dosing regimen (ie, 150 mg once daily) have not demonstrated increased benefit or toxicity in patients with invasive candidiasis (Betts, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esophageal candidiasis: 50 mg once daily with no loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant enzyme inducer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients receiving rifampin: 70 mg caspofungin once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients receiving carbamazepine, dexamethasone, phenytoin, nevirapine, or efavirenz: May require an increase in caspofungin dose to 70 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment",
"     </b>",
"     (based on adult data):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment (Child-Pugh score 5 to 6): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hepatic impairment (Child-Pugh score 7 to 9): Decrease daily dose by 30%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancidas&reg;: 50 mg [contains sucrose 39 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancidas&reg;: 70 mg [contains sucrose 54 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by slow I.V. infusion over 1 hour (manufacturer); higher doses (eg, 150 mg) have been infused over ~2 hours (Betts, 2009); maximum concentration of 0.5 mg/mL diluted in NS, LR, 0.45% sodium chloride. Do not mix or coinfuse with other medications. Do not use diluents containing dextrose.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F146818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, amiodarone, azithromycin, aztreonam, bumetanide, carboplatin, cisplatin, cyclosporine, daptomycin, daunorubicin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doripenem, doxorubicin, epinephrine, etoposide phosphate, famotidine, fentanyl, fluconazole, ganciclovir, gentamicin, hydralazine, hydrocortisone sodium succinate, hydromorphone, ifosfamide, imipenem/cilastatin, insulin (regular), linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, metronidazole, midazolam, milrinone, mitomycin, morphine, mycophenolate, norepinephrine, ondansetron, phenylephrine, potassium chloride, quinupristin/dalfopristin, tacrolimus, telavancin, tobramycin, vancomycin, vasopressin, vincristine, voriconazole.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B lipid complex, amphotericin B liposomal, ampicillin, cefazolin, cefepime, ceftazidime, ceftriaxone, clindamycin, cytarabine, ertapenem, furosemide, heparin, methylprednisolone sodium succinate, nafcillin, piperacillin/tazobactam, potassium phosphate, sulfamethoxazole/trimethoprim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, ciprofloxacin, levofloxacin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store lyophilized vial in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); reconstitute 50 mg or 70 mg vial with 10.8 mL of NS (consult manufacturer's prescribing information for details); reconstituted solution may be stored at room temperature (&le;25&deg;C or &le;77&deg;F) for 1 hour prior to preparation of the infusion solution; final infusion solution may be stored at room temperature (&le;25&deg;C or &le;77&deg;F) for 24 hours or for 48 hours in the refrigerator; caspofungin is not stable in dextrose-containing solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (ie, amphotericin B, lipid formulations of amphotericin B, and/or itraconazole); candidemia, intra-abdominal abscess, peritonitis, and pleural space infection caused by susceptible",
"     <i>",
"      Candida",
"     </i>",
"     species; esophageal candidiasis; empiric therapy of presumed fungal infection in febrile neutropenic patients (FDA approved in ages &ge;3 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F146817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hyper-/hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, mucosal inflammation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hemoglobin decreased, hematocrit decreased, WBC decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Albumin decreased, bilirubin increased, serum alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Infection (central line), phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Blood urea nitrogen increased, hematuria, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pleural effusion, pneumonia, respiratory distress, respiratory failure, rales",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infusion reactions, septic shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal distention, anaphylaxis, anorexia, anxiety, appetite decrease, arrhythmia, arthralgia, atrial fibrillation, back pain, bacteremia, bradycardia, cardiac arrest, coagulopathy, confusion, constipation, depression, dizziness, dyspepsia, dystonia, edema, epistaxis, erythema multiforme, fatigue, febrile neutropenia, fluid overload, flushing, hematuria, hepatic necrosis, hepatomegaly, hepatotoxicity, hypercalcemia, hyperkalemia, hypoxia, infusion site reactions (pain/pruritus/swelling), insomnia, jaundice, liver failure, MI, nephrotoxicity (serum creatinine &ge;2 x baseline value or &ge;1 mg/dL in patients with serum creatinine above ULN range), pain (extremities), pancreatitis, petechiae, pulmonary edema, renal failure/insufficiency, seizure, skin exfoliation, skin lesion, somnolence, stridor, Stevens-Johnson syndrome, tachypnea, thrombocytopenia, tremor, urinary tract infection, urticaria, weakness; histamine-mediated reactions (including facial swelling, bronchospasm, sensation of warmth) have been reported",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to caspofungin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dose in patients with moderate hepatic impairment; safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe hepatic impairment; use with caution and modify dose in patients on concurrent drugs which induce drug clearance such as efavirenz, nevirapine, phenytoin, dexamethasone, carbamazepine, or rifampin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transient increases of alanine transaminase (ALT) and aspartate transaminase (AST) have been reported both with and without concomitant use of cyclosporine; limit use in patients receiving cyclosporine to those in whom the potential benefit outweighs the risk",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Caspofungin may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F146777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Caspofungin should be used during pregnancy only if potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, serum potassium, CBC, hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits synthesis of beta (1,3)-D-glucan, an essential cell wall component of susceptible fungi",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF concentrations: Nondetectable [&lt;10 ng/mL (n=1)] (S&aacute;ez-Llorens, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via hydrolysis and N-acetylation in the liver; undergoes spontaneous chemical degradation to an open-ring peptide and hydrolysis to amino acids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Beta (distribution): 9-11 hours (~8 hours in children &lt;12 years); terminal: 40-50 hours; beta phase half-life is 32% to 43% lower in pediatric patients than in adult patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 35% of dose excreted in feces primarily as metabolites; 41% of dose excreted in urine primarily as metabolites; 1.4% of dose excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Betts RF, Nucci M, Talwar D, et al, \"A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(12):1676-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/19419331/pubmed\" id=\"19419331\" target=\"_blank\">",
"        19419331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&aacute;ez-Llorens X, Macias M, Maiya P, et al, \"Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less Than 3 Months of Age,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2009, 53(3):869-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/19075070/pubmed\" id=\"19075070\" target=\"_blank\">",
"        19075070",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Adamson PC, Seibel NL, et al, &ldquo;Pharmacokinetics (PK) of Caspofungin (CAS) in Pediatric Patients (#M-896),&rdquo; 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept 27-30, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Adamson PC, Seibel NL, et al, \"Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(11):4536-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/16251293/pubmed\" id=\"16251293\" target=\"_blank\">",
"        16251293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Teppler H, Donowitz GR, et al, &ldquo;Caspofungin Versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients With Persistent Fever and Neutropenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(14):1391-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21237/abstract-text/15459300/pubmed\" id=\"15459300\" target=\"_blank\">",
"        15459300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12914 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21237=[""].join("\n");
var outline_f20_47_21237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146788\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146789\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045813\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442199\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045806\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146769\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146756\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045817\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146818\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045809\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045816\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146817\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045820\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045805\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045804\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298979\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146764\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146766\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146777\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045812\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045803\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045819\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12914|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=related_link\">",
"      Caspofungin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/3/3124?source=related_link\">",
"      Caspofungin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21238="Liraglutide: Drug information";
var content_f20_47_21238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liraglutide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/42/43685?source=see_link\">",
"    see \"Liraglutide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9844180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9832447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Victoza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10304108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Victoza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9844226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9844261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose is intended to reduce GI symptoms; does not provide effective glycemic control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of type 2 diabetes:",
"     </b>",
"     SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     In the event of a missed dose, the once daily regimen can be resumed with the next scheduled dose (an extra dose or an increase in the next dose should not be attempted); if &gt;3 days have passed since the last liraglutide dose, reinitiate therapy at 0.6 mg/day to avoid GI symptoms and titrate according to prescriber discretion.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9844262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9844263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Mild-to-severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, use with caution, due to limited experience and reports of acute renal failure and exacerbation of chronic renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate-to-severe impairment: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9844284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Mild-to-severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution, due to limited experience.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Mild-to-severe impairment: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9844294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Victoza&reg;: 6 mg/mL (3 mL) [contains propylene glycol 14 mg/3 mL; prefilled pen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9844224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9844182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199170.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199170.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9844289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Use only if clear, colorless, and free of particulate matter. Administer via injection in the upper arm, thigh, or abdomen. Administer without regard to meals or time of day. Change needle with each administration. Do not share pens between patients even if needle is changed.  If using concomitantly with insulin, administer as separate injections (do",
"     <b>",
"      not",
"     </b>",
"     mix); may inject in the same body region as insulin, but not adjacent to one another.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9844228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9844181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if pens are shared among multiple patients. Steps should be taken to prohibit sharing of pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9844236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence reported in monotherapy trials unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Nausea (28%), diarrhea (17%), vomiting (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hyperbilirubinemia (monotherapy and combination trials: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (monotherapy and combination trials: 2% [includes rash, erythema])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antiliraglutide antibodies (low titers [concentrations not requiring dilution of serum]; monotherapy and combination trials: 9%), cross-reacting antiliraglutide antibodies to native GLP-1 (monotherapy: 7%; combination trials: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, angioedema, anaphylactic reactions, chronic renal failure exacerbation, dehydration, hypersensitivity reactions, hypoglycemia (most reports in patients receiving combination therapy), pancreatitis (including acute, chronic, and necrotizing), papillary thyroid carcinoma, pruritus, rash, thyroid C-cell hyperplasia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9844232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to liraglutide or any component of the formulation; history of or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9844233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; GI symptoms: Most common reactions are gastrointestinal related; these symptoms may be dose-related and may decrease in frequency/severity with gradual titration and continued use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with use; discontinue therapy in the event of a hypersensitivity reaction. Use with caution in patients with a history of angioedema to other GLP-1 receptor agonists (angioedema has been reported with other GLP-1 receptor agonists); potential for cross-sensitivity is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Cases of acute and chronic pancreatitis (including one case of fatal necrotizing pancreatitis) have been reported although conclusive evidence linking pancreatitis to liraglutide therapy has not been established; monitor for unexplained severe abdominal pain, and if pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Use with caution in patients with a history of pancreatitis, cholelithiasis, and/or alcohol abuse; limited data regarding use in patients with a history of pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid tumors:",
"     <b>",
"      [U.S. Boxed Warning] Dose- and duration- dependent thyroid C-cell tumors have developed in animal studies with liraglutide therapy; relevance in humans unknown.",
"     </b>",
"     During clinical studies, a few cases of thyroid C-cell hyperplasia were reported. Due to the finding in animal studies, patients were monitored with serum calcitonin or thyroid ultrasound during clinical trials; however, it is unknown if this is beneficial in decreasing the risk of thyroid tumors. Consultation with an endocrinologist is recommended in patients who develop elevated calcitonin concentrations.  Patients should be counseled on the risk and symptoms (eg, neck mass, dysphagia, dyspnea, persistent hoarseness) of thyroid tumors. Use is contraindicated in patients with or a family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Weight loss: Use may be associated with weight loss (likely due to reduced intake) independent of the change in hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastroparesis: Slows gastric emptying; has not been studied in patients with pre-existing gastroparesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; limited experience.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment, particularly during initiation of therapy and dose escalation. Acute renal failure and chronic renal failure exacerbation (including severe cases requiring hemodialysis) have been reported; some cases have been reported in patients with no known pre-existing renal disease. Reports primarily occurred in patients with nausea/vomiting/diarrhea or dehydration. Renal dysfunction was usually reversible with appropriate corrective measures, including discontinuation of liraglutide. Risk may be increased in patients receiving concomitant medications affecting renal function and/or hydration status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin: Concurrent use of insulin may increase the risk of hypoglycemia; dosage reduction of insulin may be required. Concurrent use with prandial insulin therapy has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea, meglitinide) may increase the risk of hypoglycemia; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral medications: Due to its effects on gastric emptying, liraglutide may reduce the rate and extent of absorption of orally-administered drugs; use with caution in patients receiving medications with a narrow therapeutic window or require rapid absorption from the GI tract.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: Not recommended for first-line therapy in patients inadequately controlled on diet and exercise alone. Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9922622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: GLP-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9844241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol may cause hypoglycemia. Management: Avoid ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9844229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9844844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic in animal reproduction studies. There are no adequate or well-controlled studies in pregnant women; use only if potential benefit outweighs possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9844231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9844285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Victoza Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18 mg/3 mL (3 mL): $182.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9844291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma glucose, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9844246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Victoza (AR, AT, AU, BE, BR, CH, CL, CZ, DE, DK, EE, FR, GB, IE, IL, IN, MY, NL, NO, NZ, PL, PT, RU, SE, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9844244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liraglutide is a long acting analog of human glucagon-like peptide-1 (GLP-1) (an incretin hormone) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Liraglutide administration results in decreases in hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     by approximately 1%.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9844247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : SubQ: ~13 L; I.V.: 0.07 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Endogenously metabolized by dipeptidyl peptidase IV (DPP-IV) and endogenous endopeptidases (Croom, 2009); metabolism occurs slower than that seen with native GLP-1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: ~55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: ~13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (6%, as metabolites); feces (5%, as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buse JB, Rosenstock J, Sesti G, et al, &ldquo;Liraglutide Once a Day Versus Exenatide Twice a Day for Type 2 Diabetes: a 26-week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)&rdquo;,",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9683):39-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/19515413/pubmed\" id=\"19515413\" target=\"_blank\">",
"        19515413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Croom KF and McCormack PL, &ldquo;Liraglutide: A Review of Its Use in Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2009, 69(14):1985-2004.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/19747013/pubmed\" id=\"19747013\" target=\"_blank\">",
"        19747013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garber A, Henry R, Ratner R, et al, &ldquo;Liraglutide Versus Glimepiride Monotherapy for Type 2 Diabetes (LEAD-3 Mono): A Randomised, 52-week, Phase III, Double-Blind, Parallel-Treatment Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9662):473-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/18819705/pubmed\" id=\"18819705\" target=\"_blank\">",
"        18819705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marre M, Shaw J, Brandle M, et al, &ldquo;Original Article: Treatment Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea Over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared With Adding Rosiglitazone or Placebo in Subjects With Type 2 Diabetes (LEAD-1 SU),&rdquo;",
"      <i>",
"       Diabetic Medicine",
"      </i>",
"      , 2009, 26(3):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/19317822/pubmed\" id=\"19317822\" target=\"_blank\">",
"        19317822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nauck M, Frid A, Hermansen K, et al, &ldquo;Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 Study,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):84-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/18931095/pubmed\" id=\"18931095\" target=\"_blank\">",
"        18931095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell-Jones D, Vaag A, Schmitz O, et al, &ldquo;Liraglutide vs Insulin Glargine and Placebo in Combination With Metformin and Sulfonylurea Therapy in Type 2 Diabetes Mellitus (LEAD-5 met+SU): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Diabetolosia",
"      </i>",
"      , 2009, 52(10):2046-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/19688338/pubmed\" id=\"19688338\" target=\"_blank\">",
"        19688338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheife RT (editor), &ldquo;Liraglutide: A New Option for the Treatment of Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(12 part 2): 23s-67s.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zinman B, Gerich J, Buse JB, et al, &ldquo;Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients WithType 2 Diabetes (LEAD-4 Met+TZD),&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(7):1224-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/47/21238/abstract-text/19289857/pubmed\" id=\"19289857\" target=\"_blank\">",
"        19289857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9522 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-5AC2A9890B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21238=[""].join("\n");
var outline_f20_47_21238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339635\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844180\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9832447\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10304108\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844226\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844262\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844263\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844284\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844294\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844224\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844182\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844289\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844228\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844181\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844236\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844232\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844233\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299609\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844241\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844229\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844844\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844231\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844285\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322813\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844291\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844246\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390244\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844244\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844247\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9522|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/42/43685?source=related_link\">",
"      Liraglutide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21239="Joint aspiration or injection in children: Indications, technique, and complications";
var content_f20_47_21239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint aspiration or injection in children: Indications, technique, and complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21239/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/47/21239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint aspiration and injections are used for diagnostic and therapeutic purposes in the care of children with arthritis.",
"   </p>",
"   <p>",
"    The indications and complications of intra-articular aspiration and injection in children are reviewed here. Details regarding the medications used, and the benefits of this procedure for specific conditions, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link&amp;anchor=H20#H20\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Management\", section on 'Intraarticular glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H2046432#H2046432\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Intraarticular joint injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary reason for joint aspiration is to assist in the diagnosis of inflamed joints (ie, arthritis), especially to determine whether infection is the cause of inflammation. Therapeutic injection generally involves the administration of corticosteroids to suppress joint inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with arthritis, joint aspiration is most often performed to differentiate bacterial (septic) arthritis from other inflammatory conditions. Empiric antibiotic therapy is administered promptly after aspiration in all patients with signs and symptoms suggestive of septic arthritis until culture results are available. If bacteria are detected by microscopic examination of the synovial fluid, empiric antibiotic therapy is mandatory until culture results are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H12#H12\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the joint inflammation is not thought to be infectious in origin, arthrocentesis is not generally necessary in children because it is of limited diagnostic value. The varied forms of non-infectious childhood arthritis are usually not reliably distinguished from one another based upon joint fluid analysis. For example, the diagnosis of the different forms of juvenile idiopathic arthritis is based upon clinical parameters. In addition, gout and other crystal-induced inflammatory conditions, in which diagnostic arthrocentesis is helpful, are extremely rare in children and adolescents. However, it must be remembered that children with documented juvenile idiopathic arthritis may subsequently develop infection in a concurrently arthritic joint, and thereby require joint aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link&amp;anchor=H5#H5\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link&amp;anchor=H8#H8\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H3#H3\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Therapeutic indications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Joint aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint aspiration may be both diagnostic and therapeutic in patients with pain due to joint distension from fluid accumulation. However, fluid is likely to rapidly reaccumulate if additional medication is not given. In addition, repeated aspiration has been shown to limit discomfort and joint damage in children with septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], but surgical drainage remains the preferred procedure for fluid removal, especially if it is purulent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Joint injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-articular corticosteroid injections are often used to treat inflammatory joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In children with a single inflamed joint with an inadequate response to oral therapy, intra-articular injection should be considered to improve clinical outcome. This was illustrated in one study that demonstrated intra-articular steroids prevented leg length discrepancy in children with persistent disease activity in only one knee [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most centers,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/45/40656?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide is the agent of choice because of its long duration of action compared to other steroid preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of intra-articular steroids as adjunctive therapy in children with pauciarticular and polyarticular JIA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link&amp;anchor=H20#H20\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Management\", section on 'Intraarticular glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H2046432#H2046432\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Intraarticular joint injection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with septic arthritis, it is not necessary to inject antibiotics directly into an infected joint. Antibiotics given intravenously reach excellent concentrations in the synovial fluid. In addition, antimicrobials may cause an increased inflammatory response when injected into the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to arthrocentesis or intra-articular injection of a noninfectious joint include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection of the overlying skin or soft tissue",
"     </li>",
"     <li>",
"      Bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Allergy to any of the medications being considered for injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrocentesis or joint injection should be performed by experienced practitioners following an explanation of the process, benefits, and risks to the patient and family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children will tolerate arthrocentesis in the office setting with the aid of local anesthesia and appropriate reassurance. However, conscious sedation or general anesthesia should be used in children with severe phobias, children who cannot cooperate, and children receiving multiple joint injections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the following local anesthetic agents can be administered alone or as a combination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14370?source=see_link\">",
"       Ethyl chloride",
"      </a>",
"      spray: Ethyl chloride is administered as a rapidly evaporating coolant often with good effects.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      : One percent lidocaine is injected into the surrounding skin and subcutaneous tissues providing local anesthesia. In patients requiring intra-articular steroid injection, lidocaine is typically mixed with the steroid preparation to reduce pain caused by the injection of steroids into the joint space. Because the methylparaben preservatives in lidocaine may decrease the sensitivity of synovial fluid culture, lidocaine should not be injected into the joint prior to obtaining fluid samples for culture. However, this does not preclude its use to anesthetize the skin and soft tissues prior to aspiration.",
"     </li>",
"     <li>",
"      EMLA cream: EMLA cream (combination of topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      2.5 percent and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      2.5 percent) has been used routinely to prevent the pain of needle insertion in children. However, a double-blinded, randomized, placebo-controlled trial found no significant difference in pain control between EMLA cream and placebo in a trial of 31 children undergoing joint injection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Conscious sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If conscious sedation is necessary, the appropriate anesthesia personnel should determine the choice of agents and procedure. While many clinicians feel there may be less \"trauma\" to the child, the additional preparation time and process may actually accentuate the anxiety of the child and parents. The additional personnel and equipment also result in a substantial increase in cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment should be appropriate to the size of the patient and effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Needle size",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 18- to 22-gauge needle should be used for arthrocentesis of the knee, ankle, hip, elbow, or shoulder. Small needles (ie, 25-gauge) should be used for smaller joints such as the interphalangeal joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Syringe size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syringe size is dependent upon the amount of fluid the clinician intends to remove. Unless the effusion is large and directly causing pain (by distention), only a small amount (5 to 10 mL) needs to be removed for diagnostic purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sterile preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate aseptic technique should be used when performing joint",
"    <span class=\"nowrap\">",
"     aspiration/injection.",
"    </span>",
"    The area should be thoroughly cleaned with povidone-iodine. A sterile drape may be used and sterile gloves are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anatomic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician performing the procedure should have a thorough knowledge of the anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The approach for arthrocentesis is chosen to provide access to the joint capsule with the least bony obstruction and to avoid neurovascular bundles [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/19\">",
"     19",
"    </a>",
"    ]. The preferred anatomic approaches for the following joints are shown in the accompanying figures (",
"    <a class=\"graphic graphic_figure graphicRef52630 graphicRef63588 graphicRef53804 graphicRef81500 graphicRef52531 graphicRef75451 graphicRef51897 graphicRef72665 \" href=\"UTD.htm?39/53/40794\">",
"     figure 1A-H",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should always aspirate before injecting to confirm (by obtaining joint fluid) that the needle is in the joint space [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/20\">",
"     20",
"    </a>",
"    ]. Following aspiration, the syringe needs to be changed. Clinicians often find it is difficult to twist off the needle to change syringes while the needle remains in the patient's joint. To facilitate the exchange of syringes, a sterile hemostat can be used to hold and stabilize the needle within the joint space while changing syringes. Alternatively, a \"reciprocating syringe\" enables one to aspirate and inject a joint using the same needle without having to exchange syringes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this setup is somewhat clumsy to handle and complicates the initial approach for aspiration.",
"   </p>",
"   <p>",
"    The joint should not be injected with corticosteroids if the fluid removed appears purulent (infected).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Synovial fluid collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid should be collected in a heparinized syringe so that clot formation does not preclude enumeration of leukocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the most commonly used imaging modality to assist in the",
"    <span class=\"nowrap\">",
"     aspiration/injection",
"    </span>",
"    of a joint. For example,",
"    <span class=\"nowrap\">",
"     aspiration/injection",
"    </span>",
"    of the hip is best done with ultrasound guidance. The attachment of a needle guide to the ultrasound probe allows visualization of the needle as it passes into the joint capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/22\">",
"     22",
"    </a>",
"    ]. Ultrasonography can also be helpful when injecting the ankle and other joints which are difficult to approach. The ready availability of ultrasonography has made it the technique of choice for these procedures when a skilled ultrasonographer who is comfortable with children is available.",
"   </p>",
"   <p>",
"    Computerized tomography has been successfully used to guide",
"    <span class=\"nowrap\">",
"     aspiration/injection",
"    </span>",
"    of the temporomandibular joint in children with juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link&amp;anchor=H20#H20\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Management\", section on 'Intraarticular glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Post-injection care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in adults have demonstrated that patients placed on 24 hours of bed rest following intra-articular knee injection had a better outcome than those who were encouraged to ambulate immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most pediatric rheumatologists recommend avoiding excessive activity (eg, physical education class) over the 24 hours following injection, but do not require bed rest. In addition, passive range of motion following injection is performed to both distribute the injected materials within the joint and to evaluate range of motion in the anesthetized joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, complications due to joint aspiration or injections are infrequent and rarely serious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Post injection inflammatory reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inflammatory reaction thought to be secondary to irritation of the synovium by microcrystals of steroid can follow intra-articular steroid injections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/26\">",
"     26",
"    </a>",
"    ]. Although seen in children, this inflammatory reaction is very uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Post injection inflammatory reaction resolves spontaneously within two to three days and is treated with local application of ice and appropriate analgesics. If there is marked heat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain, repeat aspiration to exclude possible infection is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Subcutaneous atrophy and depigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous atrophy and depigmentation occur if there has been leakage of the long acting corticosteroid into the soft tissues at the time of intra-articular steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/30\">",
"     30",
"    </a>",
"    ]. The reported incidence of this complication varies from 1 to 8 percent of intra-articular steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/29,31,32\">",
"     29,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intra-articular calcifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small calcifications may be seen on radiographs following intra-articular steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Almost all patients are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/29,33,34\">",
"     29,33,34",
"    </a>",
"    ]. The pathogenesis of these calcifications is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of introducing infection during joint",
"    <span class=\"nowrap\">",
"     aspiration/injection",
"    </span>",
"    always exists. Preventive steps to avoid this complication include use of aseptic technique and avoiding injection if there is bacteremia or overlying tissue infection. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Sterile preparation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any invasive procedure, the possibility of bleeding exists. Hemarthrosis following injection is extremely uncommon. Aspiration of a large amount of blood at the time of the procedure suggests the possibilities of trauma, a bleeding disorder (eg, hemophilia), or pigmented villonodular synovitis.",
"   </p>",
"   <p>",
"    Although infrequently encountered clinically, the risk of hemorrhage is increased in patients with a low platelet count. If necessary the patient can be given a platelet transfusion, but there needs to be an urgent reason for doing the aspiration in the face of a very low platelet count. In this setting, consultation with a pediatric hematologist is useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Effects on growing articular cartilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effect of corticosteroids upon articular cartilage in childhood are limited, but suggest there is no long-term negative effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small study of 14 children with chronic arthritis, magnetic resonance imaging was performed before, and 7 weeks and 13 months after steroid injection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/36\">",
"       36",
"      </a>",
"      ]. There was no evidence of cartilage deterioration and no effect upon skeletal growth.",
"     </li>",
"     <li>",
"      In a second study, 30 children were followed with plain radiographs after intra-articular steroid injections for chronic arthritis. No evidence of cartilage damage was found [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Additional precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians performing joint aspiration in a child with a joint effusion and pain should always evaluate carefully for pain in the surrounding bones as well as in the joint. Children with early osteomyelitis may develop a sterile sympathetic effusion (which appears benign) in the proximate joint. Sympathetic effusions may also occur in children with leukemia or other neoplastic conditions. Failure to recognize these conditions in a timely fashion may lead to a worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SYSTEMIC EFFECTS OF INTRA-ARTICULAR GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the injection of intra-articular steroids patients often note improvement in joints that were not injected suggesting that some corticosteroid enters the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Studies in both children and adults have noted transient suppression of endogenous cortisol following injection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21239/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, none developed signs or symptoms of adrenal suppression (eg, Cushing's syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint aspiration and injections are used for diagnostic and therapeutic purposes in the care of children with inflamed joints.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspiration is useful in excluding infection both in children with known underlying inflammatory condition and those without known predisposing factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injection of corticosteroids into inflamed joints may provide prompt relief of symptoms that have not responded to oral medications. Injections should not be performed in infected joints. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Therapeutic indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Joint aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      injection should only be performed by experienced clinicians. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many children will tolerate arthrocentesis in the office setting with the aid of local anesthesia and appropriate reassurance. However, conscious sedation or general anesthesia should be used in children with severe phobias, children who cannot cooperate, and children receiving multiple joint injections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Joint aspiration or infection is performed using aseptic technique. Imaging can be used to guide proper needle placement in joints that are difficult to approach, such as the hip. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, complications due to joint aspiration or injections are infrequent and rarely serious. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/1\">",
"      Givon U, Liberman B, Schindler A, et al. Treatment of septic arthritis of the hip joint by repeated ultrasound-guided aspirations. J Pediatr Orthop 2004; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/2\">",
"      Shetty AK, Gedalia A. Management of septic arthritis. Indian J Pediatr 2004; 71:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/3\">",
"      FREYBERG RH, PATTERSON M, ADAMS CH, et al. Practical considerations of the use of cortisone and ACTH in rheumatoid arthritis. Ann Rheum Dis 1951; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/4\">",
"      HOLLANDER JL, BROWN EM Jr, JESSAR RA, BROWN CY. Hydrocortisone and cortisone injected into arthritic joints; comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951; 147:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/5\">",
"      Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/6\">",
"      Hollander JL, Jessar RA, Restifo RA, Fort HJ. A new intra-articular steroid ester with longer effectiveness. Arthritis Rheum 1961; 4:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/7\">",
"      Bird HA, Ring EF, Bacon PA. A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis. Ann Rheum Dis 1979; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/8\">",
"      Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/9\">",
"      Prober CG. Current antibiotic therapy of community-acquired bacterial infections in hospitalized children: bone and joint infections. Pediatr Infect Dis J 1992; 11:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/10\">",
"      Shore A, Rush PJ. Possible danger of intra-articular steroid injection in children with respiratory tract infections. Br J Rheumatol 1987; 26:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/11\">",
"      Cleary AG, Murphy HD, Davidson JE. Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child 2003; 88:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/12\">",
"      Harcke HT. Hip in infants and children. Clin Diagn Ultrasound 1995; 30:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/13\">",
"      Uziel Y, Berkovitch M, Gazarian M, et al. Evaluation of eutectic lidocaine/prilocaine cream (EMLA) for steroid joint injection in children with juvenile rheumatoid arthritis: a double blind, randomized, placebo controlled trial. J Rheumatol 2003; 30:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/14\">",
"      Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician 2002; 66:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/15\">",
"      Zuber TJ. Knee joint aspiration and injection. Am Fam Physician 2002; 66:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/16\">",
"      Cardone DA, Tallia AF. Diagnostic and therapeutic injection of the elbow region. Am Fam Physician 2002; 66:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/17\">",
"      Tallia AF, Cardone DA. Diagnostic and therapeutic injection of the wrist and hand region. Am Fam Physician 2003; 67:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/18\">",
"      Tallia AF, Cardone DA. Diagnostic and therapeutic injection of the shoulder region. Am Fam Physician 2003; 67:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/19\">",
"      Allen RC, Gross KR, Laxer RM, et al. Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 1986; 29:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/20\">",
"      Jones A, Regan M, Ledingham J, et al. Importance of placement of intra-articular steroid injections. BMJ 1993; 307:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/21\">",
"      Sibbitt W Jr, Sibbitt RR, Michael AA, et al. Physician control of needle and syringe during aspiration-injection procedures with the new reciprocating syringe. J Rheumatol 2006; 33:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/22\">",
"      Cavalier R, Herman MJ, Pizzutillo PD, Geller E. Ultrasound-guided aspiration of the hip in children: a new technique. Clin Orthop Relat Res 2003; :244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/23\">",
"      Arabshahi B, Dewitt EM, Cahill AM, et al. Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. Arthritis Rheum 2005; 52:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/24\">",
"      Chakravarty K, Pharoah PD, Scott DG. A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/25\">",
"      Richards AJ. Post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994; 33:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/26\">",
"      MCCARTY DJ Jr, HOGAN JM. INFLAMMATORY REACTION AFTER INTRASYNOVIAL INJECTION OF MICROCRYSTALLINE ADRENOCORTICOSTEROID ESTERS. Arthritis Rheum 1964; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/27\">",
"      Hertzberger-ten Cate R, de Vries-van der Vlugt BC, van Suijlekom-Smit LW, Cats A. Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1. Eur J Pediatr 1991; 150:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/28\">",
"      Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998; 41:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/29\">",
"      Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/30\">",
"      Cassidy JT, Bole GG. Cutaneous atrophy secondary to intra-articular corticosteroid administration. Ann Intern Med 1966; 65:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/31\">",
"      Breit W, Frosch M, Meyer U, et al. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/32\">",
"      Ravelli A, Manzoni SM, Viola S, et al. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 2001; 28:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/33\">",
"      Gilsanz V, Bernstein BH. Joint calcification following intra-articular corticosteroid therapy. Radiology 1984; 151:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/34\">",
"      Sparling M, Malleson P, Wood B, Petty R. Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/35\">",
"      Goldman RD, Benseler SM, Schneider R. Intra-articular calcifications in a child with juvenile rheumatoid arthritis. Arch Dis Child 2005; 90:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/36\">",
"      Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr 1995; 127:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/37\">",
"      Earley A, Cuttica RJ, McCullough C, Ansell BM. Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/38\">",
"      Huppertz HI, Pf&uuml;ller H. Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 1997; 24:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21239/abstract/39\">",
"      Koehler BE, Urowitz MB, Killinger DW. The systemic effects of intra-articular corticosteroid. J Rheumatol 1974; 1:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6425 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21239=[""].join("\n");
var outline_f20_47_21239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Therapeutic indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Joint aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Joint injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Conscious sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Needle size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Syringe size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sterile preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anatomic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Synovial fluid collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Post-injection care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Post injection inflammatory reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Subcutaneous atrophy and depigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intra-articular calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Effects on growing articular cartilage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Additional precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SYSTEMIC EFFECTS OF INTRA-ARTICULAR GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6425|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10048\" title=\"figure 1A\">",
"      Knee arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/41/40592\" title=\"figure 1B\">",
"      Ankle arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/48/41743\" title=\"figure 1C\">",
"      Shoulder arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/34/12832\" title=\"figure 1D\">",
"      Wrist arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/26/5536\" title=\"figure 1E\">",
"      Carpometacarpal arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35216\" title=\"figure 1F\">",
"      Tennis elbow injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/63/17407\" title=\"figure 1G\">",
"      Subacromial bursa injection in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/46/34543\" title=\"figure 1H\">",
"      Trochanteric bursa injection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=related_link\">",
"      Bacterial arthritis: Treatment and outcome in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21240="Clue cell";
var content_f20_47_21240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clue cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Wet mount showing characteristic clue cells. Note that the epithelial cells are so heavily covered by bacteria as to obscure the margins.",
"    <br>",
"     (B) A clue cell. The vaginal epithelial cell on the right has shaggy borders obscured by coccobacilli (1003 magnification). The more normal appearing epithelial cell on the left has sharper borders.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      (A) Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"      <br>",
"       (B) Reproduced with permission from: Fleisher GR, MD, Ludwig S, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21240=[""].join("\n");
var outline_f20_47_21240=null;
var title_f20_47_21241="Ventricular arrhythmias in heart failure and cardiomyopathy";
var content_f20_47_21241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ventricular arrhythmias in heart failure and cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21241/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/47/21241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias, ranging from asymptomatic ventricular premature beats (VPBs) to ventricular fibrillation (VF), are common in patients with heart failure (HF) and cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These arrhythmias fall into two broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant or potentially lethal arrhythmias, including sustained ventricular tachycardia (VT) and VF.",
"     </li>",
"     <li>",
"      Nonsustained or hemodynamically tolerated arrhythmias, including VPBs, nonsustained ventricular tachycardia (NSVT), and accelerated idioventricular rhythm (AIVR). The clinical significance of these arrhythmias is largely based upon whether or not they predict future malignant arrhythmias and sudden cardiac death (SCD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic significance of VPBs and NSVT varies with the etiology of the cardiomyopathy. In patients with left ventricular (LV) systolic dysfunction due to prior myocardial infarction (MI), VPBs and NSVT are associated with an increased risk of SCD. In contrast, in most other forms of cardiomyopathy (eg, nonischemic cardiomyopathy or valve disease), these arrhythmias do not appear to predict SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The types of ventricular arrhythmias in patients with HF or cardiomyopathy, the effect of HF therapy on these arrhythmias, and the role of electrophysiologic testing will be reviewed here. The secondary and primary prevention of SCD in these patients, including a review of the causes of death in HF, and the importance of ventricular arrhythmias in other causes of cardiomyopathy, such as hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE OF ARRHYTHMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) occur in 70 to 95 percent of patients with HF, and they may be frequent and complex [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Among patients with cardiomyopathy, VPBs may be clinically significant for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VPBs may be predictors of more malignant arrhythmias and sudden cardiac death (SCD). In patients with a prior myocardial infarction (MI), VPBs are associated with an increased risk of death. In contrast, VPBs do not appear to be associated with a worse prognosis in patients with nonischemic cardiomyopathy, although data are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/4\">",
"       4",
"      </a>",
"      ]. Regardless of the etiology of the cardiomyopathy, there is no role for pharmacologic suppression of VPBs for the purpose of reducing the risk of malignant arrhythmias or SCD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link\">",
"       \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"       \"Clinical significance and treatment of ventricular premature beats\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VPBs can cause symptoms, usually palpitations. Symptoms are generally mild, and most patients require no specific therapy. Beta blockers can help to control symptoms, but most patients with HF and cardiomyopathy already have an indication for a beta blocker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the proarrhythmic risks of antiarrhythmic drugs other than beta blockers, these medications are not used in the routine treatment of VPBs. In the rare circumstance in which a patient is severely symptomatic despite beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    appear to be safe in patients with HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In rare cases, very frequent VPBs cause or exacerbate LV dysfunction. This was illustrated in a report of 14 patients with dilated cardiomyopathy, a left ventricular ejection fraction (LVEF) &le;40 percent, and more than 20,000 VPBs in 24 hours (14",
"      <span class=\"nowrap\">",
"       VPBs/min)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/9\">",
"       9",
"      </a>",
"      ]. All patients had been treated with standard medical therapy for HF. Seven patients received additional medical therapy (mostly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ), five of whom, all with idiopathic dilated cardiomyopathy, had at least a 75 percent reduction in VPB frequency (baseline value 37,334 VPBs in 24 hours or 26",
"      <span class=\"nowrap\">",
"       VPBs/min).",
"      </span>",
"      These patients had a significant and marked improvement in LVEF at six months (49 versus 27 percent at baseline). In contrast, an increase in LVEF was not noted in the remaining patients who did not have such a reduction in VPB frequency (9 percent increase to 37 percent reduction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the five responders, only one received a new medical therapy (a beta blocker) that might have improved left ventricular function. This makes it less likely that the improvement in LVEF was the primary event, leading to a secondary reduction in VPBs. Thus, in some patients with",
"    <strong>",
"     very frequent",
"    </strong>",
"    VPBs, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    to assess possible improvement in LVEF may be beneficial as an addition to routine beta blocker therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similarly, catheter ablation of very frequent VPBs may improve left ventricular function in patients with nonischemic cardiomyopathy. This was illustrated in a nonrandomized study in which VPBs (mean 21 percent of QRS complexes) were successfully ablated in 18 of 22 patients with reduced LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/10\">",
"       10",
"      </a>",
"      ]. In these patients, mean LVEF increased from 34 to 59 percent. The four patients in whom ablation was unsuccessful experienced further deterioration in LVEF, from 34 to 25 percent, during follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsustained ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Runs of nonsustained ventricular tachycardia (NSVT) have been observed on ambulatory monitoring in 50 to 80 percent of patients with HF or cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ]. The clinical significance of NSVT can be considered in a similar manner to that of VPBs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSVT may be predictive of future malignant arrhythmias and mortality. An association between NSVT and mortality has been shown in patients with ischemic and hypertrophic cardiomyopathy, but not in most other forms of cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"       \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is generally no role for the pharmacologic suppression of NSVT for the purpose of reducing the risk of malignant arrhythmias or sudden cardiac death. However, NSVT can be an indication for electrophysiology study and possible implantable cardioverter-defibrillator (ICD) therapy in selected patients with a prior MI and ischemic cardiomyopathy, and for an ICD in selected patients with hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of nonsustained ventricular tachycardia\", section on 'Prevention of SCD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H4#H4\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'High-risk patients'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H13#H13\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'High-risk clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSVT is often asymptomatic, but some patients experience palpitations, lightheadedness, presyncope, or dyspnea. Because many of the symptoms that may be attributed to NSVT are vague and nonspecific, it is important to try to correlate symptoms to episodes of NSVT before initiating therapy. In patients with symptoms due to NSVT, options include beta blockers, for which most patients already have an indication, catheter ablation, and, in rare cases of severe and refractory symptoms,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"       \"Management of nonsustained ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In rare cases, very frequent NSVT can contribute to or exacerbate LV dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Accelerated idioventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accelerated idioventricular rhythm (AIVR), which has also been called \"slow VT\", arises below the atrioventricular node and has, by definition, a rate between 50 and 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    (",
"    <a class=\"graphic graphic_waveform graphicRef52385 \" href=\"UTD.htm?39/57/40856\">",
"     waveform 1",
"    </a>",
"    ). In patients with sinus node dysfunction, AIVR can be an escape rhythm, while in other cases it reflects an abnormal ectopic focus in the ventricle that competes with the sinus node. In either case, AIVR is accelerated by sympathetic stimulation and circulating catecholamines.",
"   </p>",
"   <p>",
"    AIVR occurs in approximately 8 percent of patients with HF or cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/12\">",
"     12",
"    </a>",
"    ]. It also occurs in up to 50 percent of patients during an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Accelerated idioventricular rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most episodes of AIVR are transient and require no treatment. Furthermore, pharmacologic treatment is CONTRAINDICATED if AIVR is an escape rhythm, since suppression of the pacemaker focus can result in asystole. Patients with symptomatic AIVR due to sinus node dysfunction may benefit from atrial pacing. There are no convincing data linking AIVR to sustained VT or VF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sustained VT or VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the high prevalence of VPBs and NSVT in patients with HF or cardiomyopathy, sustained VT is unusual, occurring in &le;5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ]. Patients with spontaneous sustained VT are at high risk for SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HF or cardiomyopathy who are survivors of SCD due to unstable VT or VF, and have stable sustained VT are typically treated with an ICD for secondary prevention. The supporting data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Electrical storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical storm, also referred to as VT storm or arrhythmic storm, refers to multiple recurrences of ventricular arrhythmias (VT or VF) over a short period of time (eg, three or more episodes during a 24 hour period). This is a relatively rare phenomenon, and both terminology and definitions vary. Electrical storm is most commonly associated with acute MI and coronary artery disease, but can also develop in patients with dilated cardiomyopathy.",
"   </p>",
"   <p>",
"    The incidence of electrical storm appears to be higher among patients receiving ICDs for secondary prevention than among those receiving ICDs for primary prevention. Implications and treatment of electrical storm are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=see_link\">",
"     \"Electrical storm and incessant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5570717\">",
"    <span class=\"h1\">",
"     IMPACT OF SLEEP DISORDERED BREATHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disordered breathing (SDB), presenting as either obstructive sleep apnea (OSA) or central sleep apnea syndrome (CSA, including Cheyne-Stokes breathing) occurs commonly in patients with heart failure and is associated with increased cardiac mortality. The relationship between SDB and ventricular arrhythmias was investigated in a study of 283 HF patients (170 with no or mild SDB, and 113 with untreated SDB) with ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/15\">",
"     15",
"    </a>",
"    ]. Time periods to first monitored ventricular arrhythmias (VT or VF) and to first appropriate cardioverter defibrillator therapy were significantly shorter in patients with SDB. Multivariate models demonstrated that SDB (apnea hypopnea index &ge;15",
"    <sup>",
"    </sup>",
"    event per hour) was an independent risk factor for ventricular arrhythmias and appropriate cardioverter-defibrillator therapies. However, it remains to be determined whether therapy for SDB can reduce ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope in the setting of severe cardiomyopathy and HF requires special consideration. Although these patients may have syncope due to any of the usual causes, they are more likely than other patients to have an arrhythmic etiology. Thus, syncope in this population requires careful evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluating and managing syncope in HF patients is complicated by the variety of potential etiologies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope may be due to a poorly tolerated but transient arrhythmia. Although both bradyarrhythmias and tachyarrhythmias can occur in any patient, those with HF and cardiomyopathy have a higher incidence of these arrhythmias.",
"     </li>",
"     <li>",
"      HF patients can experience syncope or near-syncope due to medications or hemodynamic abnormalities related to their underlying cardiac disease.",
"     </li>",
"     <li>",
"      Syncope can be due to any of the etiologies found in other patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"       \"Pathogenesis and etiology of syncope\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, HF patients who experience a syncopal event should undergo a thorough evaluation. This evaluation often includes an electrophysiology study, both to exclude the possibility of a bradyarrhythmic cause and to attempt to induce ventricular arrhythmias. Patients in whom no etiology of syncope is found are said to have unexplained syncope. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Role of EP testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is associated with an increased risk of SCD in patients with HF and cardiomyopathy, even if an arrhythmic cause cannot be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated 491 patients with NYHA class III to IV HF due to nonischemic cardiomyopathy who had a mean LVEF of 20 percent (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/17\">",
"       17",
"      </a>",
"      ]. At a mean follow-up of one year, the SCD rate was significantly increased in patients with syncope (45 versus 12 percent in those without syncope).",
"     </li>",
"     <li>",
"      In studies in which an ICD was placed because of unexplained syncope or near syncope, there was a high rate of appropriate ICD shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. At follow-up ranging from 1.5 to 3 years, 30 to 40 percent received appropriate shocks for VT or VF. One of these series consisted of 14 patients with syncope, a mean LVEF of 26 percent, a negative electrophysiology study; seven had appropriate shocks at a mean follow-up of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ICD therapy in patients with syncope and heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H6#H6\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Patients with syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFECT OF HF THERAPY ON VENTRICULAR ARRHYTHMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF and ventricular arrhythmias should have their HF treated aggressively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard therapy for HF due to systolic dysfunction consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A beta blocker such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"     </li>",
"     <li>",
"      An angiotensin converting enzyme (ACE) inhibitor",
"     </li>",
"     <li>",
"      An angiotensin II receptor blocker (ARB) in selected patients",
"     </li>",
"     <li>",
"      An aldosterone antagonist in selected patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and occasionally other inotropic agents are used for symptom control, while diuretics are given for congestive symptoms. Many of these drugs can affect the incidence of arrhythmic death in patients with HF or cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial part of the survival benefit seen with beta blockers in patients with HF is due to a significant reduction in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In the MERIT-HF trial, for example, there were significantly fewer SCDs (3.9 versus 6.6 percent) and fewer deaths from worsening of HF (1.5 versus 2.9 percent) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/22\">",
"     22",
"    </a>",
"    ]. The proportion of SCDs decreased and those due to HF increased with increasing severity of HF. In CIBIS-II, the survival benefit from beta blocker therapy was primarily due to a reduction in SCD (3.6 versus 6.3 percent), with only a nonsignificant trend toward fewer deaths from HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors improve survival in all stages of HF. However, there are conflicting data as to whether ACE inhibitors reduce SCD. Some major trials &mdash; CONSENSUS, SOLVD, and SAVE &mdash; found that the survival benefit was primarily due to slowed progression of HF, with little or no reduction in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/25-28\">",
"     25-28",
"    </a>",
"    ], while others &mdash; V-HeFT II, TRACE, and AIRE &mdash; showed a significant reduction in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of trials of 15,104 patients within 14 days of an acute MI found that ACE inhibitor therapy modestly but significantly reduced the risk of SCD (odds ratio 0.80, absolute benefit about 1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/33\">",
"     33",
"    </a>",
"    ]. However, as noted above, 45 percent of patients who died suddenly in AIRE had severe or worsening HF prior to their death, and only 39 percent of sudden deaths were thought to be due to arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ARBs appear to be as or perhaps slightly less beneficial than ACE inhibitors in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/34\">",
"     34",
"    </a>",
"    ]. The major ARB trial CHARM noted a clear survival benefit but did not report data on SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/35\">",
"     35",
"    </a>",
"    ]. ELITE II, which directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , found a higher rate of SCD with losartan that was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/34\">",
"     34",
"    </a>",
"    ]. This might suggest that ARBs alone are unlikely to have a major impact on SCD in HF patients.",
"   </p>",
"   <p>",
"    On the other hand, the addition of ARB to ACE inhibitor therapy in patients with HF in the CHARM-Added trial was found to reduce the rate of SCD as well as the rate of death from worsening heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aldosterone antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    significantly reduce overall mortality and SCD in patients with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. They also reduce the frequency of VPBs and NSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/39\">",
"     39",
"    </a>",
"    ]. These benefits may reflect a reduction in aldosterone effect on the heart",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the maintenance of a higher serum potassium concentration. Patients treated with these drugs must be monitored carefully because of the risk of hyperkalemia, which is magnified by the concurrent presence of decreased renal perfusion and angiotensin inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Digoxin and other inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is an effective drug for reducing the symptoms from HF. The DIG trial demonstrated that digoxin, compared to placebo, produced a significant reduction in hospitalizations but had no net benefit on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/41\">",
"     41",
"    </a>",
"    ]. Although digoxin significantly reduced mortality from pump failure, this was offset by an apparent increase in mortality from arrhythmia that was not statistically significant.",
"   </p>",
"   <p>",
"    However, the outcome varied significantly with the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/42\">",
"     42",
"    </a>",
"    ]. All-cause mortality at 37 months in men was significantly",
"    <strong>",
"     lower",
"    </strong>",
"    for those with a serum digoxin concentration of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    compared to placebo (29.9 versus 36.2 percent); in comparison, mortality was",
"    <strong>",
"     increased",
"    </strong>",
"    in men with a serum digoxin concentration above 1.2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\", section on 'Optimal digoxin level'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A proarrhythmic effect has also been noted with other inotropic agents used for the treatment of HF including beta adrenergic agonists and phosphodiesterase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational and retrospective data suggest that statins might be of benefit in patients with HF and cardiomyopathy, regardless of the presence of coronary artery disease. The possible mechanisms of benefit, other than treatment of coronary disease that may have been unrecognized, are not known. Statins have a variety of lipid-independent (pleiotropic) effects that could contribute to improved outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential impact of statins on the incidence of SCD in patients with nonischemic cardiomyopathy was illustrated in a retrospective analysis of patients in the DEFINITE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the 458 patients enrolled, 110 were receiving statin therapy at the time of their first event or at the conclusion of the trial. Patients treated with a statin had significantly lower rates of arrhythmic sudden death and total mortality compared to those not treated with a statin (0.9 versus 5.2 percent and 4.5 versus 18.4 percent, respectively). Larger randomized trials that should provide more definitive data on the role of statins in nonischemic cardiomyopathy are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ROLE OF EP TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiology (EP) testing can serve several purposes in patients with HF and cardiomyopathy:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EP testing can demonstrate the mechanisms of induced or spontaneous arrhythmias and characterize the function of the sinus node, the AV node, and the His-Purkinje system. Thus, EP testing can assist in the diagnosis of unexplained symptoms (eg, palpitations or syncope) and arrhythmias.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for the management of ventricular arrhythmias recommend EP study in patients with HF or cardiomyopathy patients with one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sustained palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope for which there is not a clear explanation",
"     </li>",
"     <li>",
"      A wide QRS complex tachycardia of uncertain etiology",
"     </li>",
"     <li>",
"      Bundle branch reentrant tachycardia, both to confirm the diagnosis and to guide ablation in patients with nonischemic cardiomyopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the weight of evidence was considered to support (a weaker recommendation) EP testing for risk stratification in patients with a remote myocardial infarction, nonsustained ventricular tachycardia, and a left ventricular ejection fraction less than or equal to 40 percent. However, post-MI patients with an LVEF less than or equal to 30 percent fulfill MADIT-II criteria for implantable cardioverter-defibrillator (ICD) placement without requiring EP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21241/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to induce ventricular arrhythmias during EP testing is associated with an increased risk of arrhythmic events and SCD in patients with a prior MI and LV dysfunction. For this reason, EP testing is used in some post-MI patients with moderate LV dysfunction (eg, LVEF 31 to 40 percent) to determine if they are candidates for an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-MI patients with severe LV dysfunction (LVEF &le;30 percent), or advanced HF (NYHA class II or III), are considered to be at a high enough risk of SCD that ICD implantation is recommended without the need for an EP study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability to induce ventricular arrhythmias is not predictive of SCD risk in patients with nonischemic cardiomyopathy. Thus, EP testing does not have a role in risk stratification in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary and primary prevention of sudden cardiac death in HF and cardiomyopathy, often with an implantable cardioverter-defibrillator, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Types of ventricular arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) and cardiomyopathy are associated with a variety of ventricular arrhythmias. These include ventricular premature beats and nonsustained ventricular tachycardia (VT), which are the most common, and accelerated idioventricular rhythm, and sustained ventricular tachycardia or ventricular fibrillation (VF). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Type of arrhythmia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     VPBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs are present in many patients with HF, but symptoms are generally absent or mild and most patients do not require specific therapy. Possible therapy for VPBs varies with the clinical setting and is considered only for symptoms or VPBs that might depress left ventricular ejection fraction (LVEF). There is no role for pharmacologic suppression of VPBs for the purpose of reducing the risk of malignant arrhythmias or sudden cardiac death. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Ventricular premature beats'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with asymptomatic or mildly symptomatic VPBs, we recommend NOT treating with antiarrhythmic medications (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Beta blockers reduce VPBs and are indicated in most patients with HF and cardiomyopathy because of improved survival and other benefits. In patients who are taking a beta blocker and still experiencing frequent, severely symptomatic VPBs that interfere with their quality of life or that appear to reduce LVEF, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      , or catheter ablation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nonsustained VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSVT is common in patients with HF, is often asymptomatic, and, in most patients, pharmacologic suppression does not reduce the risk of malignant arrhythmias or SCD. NSVT can be an indication for electrophysiology study and possible implantable cardioverter-defibrillator (ICD) therapy in selected patients with a prior MI and ischemic cardiomyopathy, and for an ICD in selected patients with hypertrophic cardiomyopathy. Recommendations for the management of such patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of nonsustained ventricular tachycardia\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     AIVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated idioventricular rhythm (AIVR) occurs in approximately 8 percent of patients with HF or cardiomyopathy. It is usually transient and requires no treatment. Furthermore, pharmacologic treatment is CONTRAINDICATED if AIVR is an escape rhythm, since suppression of the pacemaker focus can result in asystole. Patients with symptomatic AIVR due to sinus node dysfunction may benefit from atrial pacing. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Accelerated idioventricular rhythm'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Sustained ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained VT is unusual, occurring in &le;5 percent of patients with HF, but it confers a high risk for SCD. Patients with HF or cardiomyopathy who are survivors of SCD due to unstable VT or VF, or have stable sustained VT are typically treated with an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Significance of syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope in patients with HF or cardiomyopathy may result from one of three mechanisms: a poorly tolerated but transient bradyarrhythmia or tachyarrhythmia; medications or hemodynamic abnormalities related to the underlying heart disease; or any of the other etiologies of syncope. Thus, HF patients who experience a syncopal event should undergo a thorough evaluation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Syncope'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     HF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF and ventricular arrhythmias should be treated aggressively for HF. Standard therapy for HF due to systolic dysfunction includes of the following (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Effect of HF therapy on ventricular arrhythmia'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A beta blocker such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"     </li>",
"     <li>",
"      An angiotensin converting enzyme (ACE) inhibitor",
"     </li>",
"     <li>",
"      An angiotensin II receptor blocker (ARB) in selected patients",
"     </li>",
"     <li>",
"      An aldosterone antagonist in selected patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to their hemodynamic effects, these drugs improve survival and may reduce the incidence of ventricular arrhythmias and SCD.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    improves symptoms, while the effect on mortality varies with the attained serum digoxin concentration: among men in the DIG trial, all-cause mortality at 37 months was significantly lower in those with a serum digoxin concentration of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and increased in those with a serum digoxin concentration above 1.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    compared to placebo. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Effect of HF therapy on ventricular arrhythmia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A proarrhythmic effect has also been noted with other inotropic agents used for the treatment of HF including beta adrenergic agonists and phosphodiesterase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     EP testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;EP testing can assist in the diagnosis of unexplained symptoms (eg, palpitations or syncope) and arrhythmias in patients with HF or cardiomyopathy. It is also useful in some post-MI patients with moderate LV dysfunction (eg, LVEF 31 to 40 percent) to determine if they are candidates for an implantable cardioverter-defibrillator. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Role of EP testing'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/1\">",
"      Hynes BJ, Luck JC, Wolbrette DL, et al. Arrhythmias in Patients with Heart Failure. Curr Treat Options Cardiovasc Med 2002; 4:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/2\">",
"      Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986; 57:3B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/3\">",
"      Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/4\">",
"      Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992; 85:I50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/5\">",
"      Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000; 101:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/6\">",
"      Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992; 69:82G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/7\">",
"      von Olshausen K, Sch&auml;fer A, Mehmel HC, et al. Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J 1984; 51:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/8\">",
"      Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/9\">",
"      Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998; 73:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/10\">",
"      Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007; 4:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/11\">",
"      Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998; 32:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/12\">",
"      Grimm W, Hoffmann J, Menz V, et al. Significance of accelerated idioventricular rhythm in idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 85:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/13\">",
"      Poll DS, Marchlinski FE, Buxton AE, et al. Sustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy: electrophysiologic testing and lack of response to antiarrhythmic drug therapy. Circulation 1984; 70:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/14\">",
"      Milner PG, Dimarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol 1988; 11:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/15\">",
"      Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 2011; 32:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/16\">",
"      Livanis EG, Kostopoulou A, Theodorakis GN, et al. Neurocardiogenic mechanisms of unexplained syncope in idiopathic dilated cardiomyopathy. Am J Cardiol 2007; 99:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/17\">",
"      Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/18\">",
"      Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol 2000; 85:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/19\">",
"      Grimm W, Hoffmann J J&uuml;, M&uuml;ller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/20\">",
"      Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999; 33:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/21\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/22\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/23\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/24\">",
"      The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/25\">",
"      Pratt CM, Gardner M, Pepine C, et al. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators. Am J Cardiol 1995; 75:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/26\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/27\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/28\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/29\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/30\">",
"      Fletcher RD, Cintron GB, Johnson G, et al. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation 1993; 87:VI49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/31\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/32\">",
"      K&oslash;ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/33\">",
"      Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/34\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/35\">",
"      Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/36\">",
"      Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/37\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/38\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/39\">",
"      Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/40\">",
"      Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/41\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/42\">",
"      Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/43\">",
"      Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/44\">",
"      Goldberger JJ, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21241/abstract/45\">",
"      Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 968 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21241=[""].join("\n");
var outline_f20_47_21241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE OF ARRHYTHMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Accelerated idioventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sustained VT or VF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Electrical storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5570717\">",
"      IMPACT OF SLEEP DISORDERED BREATHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFECT OF HF THERAPY ON VENTRICULAR ARRHYTHMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Digoxin and other inotropes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ROLE OF EP TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION OF SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Types of ventricular arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - VPBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nonsustained VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - AIVR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Sustained ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Significance of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HF therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      EP testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/968|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/57/40856\" title=\"waveform 1\">",
"      ECG Accelerated idioventricular rhythm tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21242="What's new in primary care internal medicine";
var content_f20_47_21242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in primary care internal medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/47/21242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21242/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21242/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/47/21242/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/47/21242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/1\">",
"     1",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/2\">",
"     2",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mediterranean diet and prevention of cardiovascular disease",
"    </span>",
"   </p>",
"   <p>",
"    A large randomized trial compared three diets in patients at high cardiovascular risk: a Mediterranean diet supplemented with olive oil, a Mediterranean diet supplemented with mixed nuts, and advice to reduce dietary fat [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/3\">",
"     3",
"    </a>",
"    ]. The trial was stopped early after a median follow-up of 4.8 years. For the primary composite cardiovascular endpoint of myocardial infarction, stroke, and cardiovascular death, event rates were similar for the Mediterranean diets supplemented with olive oil and mixed nuts, and lower than for the control diet (8.1 and 8.0 events per 1000 person-years respectively, versus 11.2 events per 1000 person-years; HR for both Mediterranean diets combined 0.71). Although this trial suggests possible substantial cardiovascular benefits from a Mediterranean diet, there was a surprisingly large reduction in events, a low total number of events (288), and the trial was stopped early for benefit. This raises concerns that the apparent benefits of a Mediterranean diet could have been overestimated, since this can be a problem in trials that are stopped early for benefit, particularly when there are also relatively few events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H20#H20\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Mediterranean diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of folate or folic acid in cancer prevention",
"    </span>",
"   </p>",
"   <p>",
"    The role of folate or folic acid in cancer prevention is uncertain. Several large observational studies have suggested a decrease in risk of colorectal and other cancers with dietary folate, while some randomized trials of folic acid supplementation have raised the possibility of harm (increased cancer risk) from folic acid supplementation. In the largest meta-analysis of individual patient data from randomized trials of folic acid for the prevention of cardiovascular disease (10 trials, n = 49,969) and colorectal adenoma (3 trials, n = 2652), during an average of 5.2 years of treatment, there was no significant difference in overall cancer incidence for patients assigned to folic acid or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/7\">",
"     7",
"    </a>",
"    ]. There was also no significant effect on the incidence of specific cancers, including cancers of the large intestine, prostate, lung, or breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H23#H23\">",
"     \"Cancer prevention\", section on 'Folate and other B vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Long-term use of postmenopausal hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) has published an updated meta-analysis of postmenopausal hormone therapy (nine trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/8\">",
"     8",
"    </a>",
"    ]. Results were largely based upon the two Women's Health Initiative trials, and the mean age of subjects was &gt;60 years. Estrogen plus progestin, as well as&nbsp;unopposed estrogen, decreased fracture risk but increased&nbsp;the risk for stroke, venous thromboembolic events, and gallbladder disease. Estrogen plus progestin increased risk for breast cancer, but unopposed estrogen decreased breast cancer risk. Based upon these data, the USPSTF continues to recommend against the use of both combined estrogen and progestin and unopposed estrogen for prevention of chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, they note that this recommendation does not apply to women considering&nbsp;hormone therapy for relief of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H91121219#H91121219\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multivitamins and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Observational studies have not identified a consistent decrease in cancer risk with multivitamin use. A large randomized trial of multivitamins, involving over 14,000 men, demonstrated a small, statistically-significant reduction in total cancer risk (HR 0.92, 95% CI 0.86-0.998) for the multivitamin group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/11\">",
"     11",
"    </a>",
"    ]. The study population was male physicians 50 years and older at recruitment, and thus generally well nourished and highly educated. With a mean follow-up of 11.2 years, there was a reduction in total cancer from 18.3 to 17.0 events per 1000 person-years; there was no impact on cancer mortality. Trials of other vitamin supplements, including limited combination supplements, have generally not shown similar effects and a meta-analysis incorporating all such trials would be helpful. While awaiting further analysis and trials, it remains uncertain whether multivitamin supplements provide added benefit to a balanced, healthful diet for most individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H48#H48\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Multivitamins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer prevention\", section on 'Vitamins and micronutrients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vitamin D and prevention of colds",
"    </span>",
"   </p>",
"   <p>",
"    A role for vitamin D in the prevention of upper respiratory infections was suggested by data from a US survey population that found a relationship between higher serum levels of 25-hydroxyvitamin D and fewer reported respiratory infections. However, in the largest randomized trial evaluating whether vitamin D supplementation can prevent upper respiratory infections, there was no difference in the incidence of colds over 18 months (two winter seasons) comparing groups who received monthly vitamin D3 injections or placebo; 25-OH vitamin D levels (comparable between groups at baseline) were 48 and 25",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for intervention and control groups respectively during the course of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link&amp;anchor=H21#H21\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Screening colonoscopy and incidence of late stage colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are no randomized trials of the effectiveness of screening colonoscopy in average-risk patients, and some observational data suggest that colonoscopy might not be effective in detecting right-sided (proximal) colon lesions. In a case-control study in four health plans in the United States in which rates of screening colonoscopy were low in both cases and matched controls (reflecting practice patterns going back 17 years), late stage (IIb or higher) colorectal cancer was associated with failure to undergo screening colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/13\">",
"     13",
"    </a>",
"    ]. The association was the same for right- and left-sided cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H16#H16\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Evidence of effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    In the largest cohort study of high-risk women, the United Kingdom Familial Ovarian Cancer Screen Study (UK FOCSS), 3563 women with a familial ovarian cancer syndrome (estimated minimum lifetime risk of 10 percent) who had declined or deferred risk reducing salpingo-oophorectomy (RRSO) were screened annually for a mean of 3.2 years with a combination of transvaginal ultrasound and CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/14\">",
"     14",
"    </a>",
"    ]. Sensitivity for the detection of incident ovarian",
"    <span class=\"nowrap\">",
"     cancer/fallopian",
"    </span>",
"    tube cancer was 81.0 to 87.5 percent. The positive predictive value of incident screening was 25.5 percent, which exceeds the threshold of 10 percent considered necessary for ovarian cancer screening. 30.8 percent (4 of 13) of incident cancers were stage I or II.&nbsp;",
"    <br/>",
"    <br/>",
"    Although&nbsp;RRSO&nbsp;remains the only reliable method of decreasing mortality from ovarian cancer in this high-risk population, this study suggests that screening&nbsp;has the potential to somewhat reduce risk for women who wish to maintain their childbearing potential until they are ready to undergo surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for ovarian cancer\", section on 'High-risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Screening for diabetes mellitus",
"    </span>",
"   </p>",
"   <p>",
"    There are few trials evaluating the benefits of screening for type 2 diabetes. In one recent trial, 33 general practices in the United Kingdom were randomly assigned to screening followed by intensive multifactorial treatment of people diagnosed with diabetes, screening followed by routine care of diabetes, and a no-screening control group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/15\">",
"     15",
"    </a>",
"    ]. Individuals were selected for participation in the trial based upon an increased risk score for diabetes. After a median follow-up of 9.6 years, there was no difference in overall mortality between the screening and control groups. Limitations of this trial included a low overall prevalence of newly diagnosed diabetes (3 percent of screened population) and a relatively brief follow-up period, given the long-term complications of diabetes require more than a decade of diabetes to develop, with morbidity or mortality associated with the complications requiring substantially more time. Additional trials examining morbidity and quality of life issues between screen-detected diabetes and diagnosis through routine clinical care are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H2377257#H2377257\">",
"     \"Screening for diabetes mellitus\", section on 'Effectiveness of early detection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rescreening for colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although colonoscopy is frequently chosen for the first-round of screening for colorectal cancer (CRC), the choice of screening modality following an initial negative study may differ. Since the risk of disease is significantly lower for second-round screening and beyond, options for subsequent testing may include no screening or testing using less-invasive or less-costly modalities. In the absence of trial data, a computer simulation model found that, compared with no screening, rescreening by any method following an initial negative colonoscopy reduced the risk of CRC&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/16\">",
"     16",
"    </a>",
"    ]. Rescreening with colonoscopy was projected to cause more complications and greater cost compared&nbsp;with other modalities (highly sensitive stool guaiac, fecal immunochemical testing, or CT colonography), with equivalent benefit measured as life-years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H3759928#H3759928\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other factors that may impact screening test choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CT colonography for colorectal cancer screening",
"    </span>",
"   </p>",
"   <p>",
"    In a study of colorectal cancer screening comparing optical colonoscopy with laxative-free CT colonography (CTC), in which stool was tagged with orally-ingested contrast material and software was used to &ldquo;electronically cleanse&rdquo; the bowel images, the sensitivity and specificity for adenomas &ge;10 mm were 91 and 85 percent for CTC and 95 and 89 percent for optical colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/17\">",
"     17",
"    </a>",
"    ]. A survey of the study participants, who underwent both procedures, indicated preference for CTC. The performance characteristics of laxative-free CTC was comparable to the performance of CTC with laxatives reported in other studies.",
"    <br/>",
"    <br/>",
"    An earlier report of a randomized trial in the Netherlands compared outcomes for two colorectal cancer screening strategies: invitation for colonoscopy or invitation for screening CT colonography (for which patients did not use a cathartic preparation) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/18\">",
"     18",
"    </a>",
"    ]. The diagnostic yield for advanced neoplasia was greater for individuals who underwent colonoscopy than for CT colonography. However, participation rates were significantly lower for those invited for colonoscopy than for colonography (22 versus 34 percent), so that the diagnostic yield for advanced neoplasia per 100 invitees was essentially the same for both strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H18#H18\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Computed tomographic colonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Flexible sigmoidoscopy for colorectal cancer screening",
"    </span>",
"   </p>",
"   <p>",
"    Results of the flexible sigmoidoscopy arm of the Prostate Lung Colorectal and Ovarian (PLCO) Screening Trial have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/19\">",
"     19",
"    </a>",
"    ]. A total of 154,900 men and women aged 55 to 74 were randomly assigned to screening with flexible sigmoidoscopy or to usual care, with median follow-up of 11.9 years. There was a 21 percent reduction in the relative risk of colorectal cancer and a 26 percent reduction in the relative risk of death from colorectal cancer, comparing the screening arm with usual care. Although the incidence of both proximal and distal CRC significantly decreased, a reduction in mortality was seen only for distal cancer. There was significant contamination in the usual care group (among whom 47 percent underwent either sigmoidoscopy or colonoscopy), suggesting that the impact of sigmoidoscopy compared to no screening might be even greater than was seen in this trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H11#H11\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Sigmoidoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GENERAL INTERNAL MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reassurance provided by diagnostic testing",
"    </span>",
"   </p>",
"   <p>",
"    Diagnostic tests are often ordered for patients with a low pretest probability of serious disease to provide reassurance, as well as to rule out illnesses. A meta-analysis of three open label randomized trials compared initial diagnostic testing (eg, cranial magnetic resonance imaging) with no testing in&nbsp;more than 700&nbsp;patients with a low probability of disease (eg, headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/20\">",
"     20",
"    </a>",
"    ].&nbsp;Illness worry (concern that symptoms may represent serious illness) was comparable for both groups in the short term (&le;3 months) and long term (&gt;3 months). Additional analyses found that testing did not reduce nonspecific anxiety or resolve symptoms, but did lead to a small decrease in the number of subsequent visits to primary care.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H15#H15\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patient understanding of acetaminophen dosing",
"    </span>",
"   </p>",
"   <p>",
"    Accidental acetaminophen overdose remains a major cause of morbidity and mortality. According to a prospective study of 500 patients tested about their understanding of acetaminophen dosing at one academic and one community internal medicine practice, up to 46 percent of patients would ingest excessive amounts of acetaminophen because they misunderstand dosing directions or fail to recognize that acetaminophen is found in more than one medication they are using [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/21\">",
"     21",
"    </a>",
"    ]. Such errors occur most often among patients with limited literacy or frequent acetaminophen use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H2#H2\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     New levonorgestrel-releasing IUD",
"    </span>",
"   </p>",
"   <p>",
"    A lower-dose (13.5 mg) levonorgestrel-releasing intrauterine device (IUD; Skyla) became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/22\">",
"     22",
"    </a>",
"    ]. It is smaller in size than the 52 mg levonorgestrel IUD (Mirena)&nbsp;and thus may be easier to insert in nulliparous women. Because of the lower levonorgestrel dose, it is approved for up to three years of use (the 52 mg dose is approved for up to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     \"Levonorgestrel: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute kidney injury after synthetic cannabinoid use",
"    </span>",
"   </p>",
"   <p>",
"    Synthetic cannabinoids, including tetrahydrocannabinol [THC], cannabidiol [CBD], and cannabinol [CBN], are analogs of naturally-occurring chemicals found in marijuana. In two small case series, synthetic cannabinoid or &ldquo;Spice&rdquo; use has been associated with reversible acute kidney injury necessitating renal replacement therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Pathologically, the injury is characterized by acute tubular necrosis and interstitial nephritis. In some instances, these previously-healthy&nbsp;young adults&nbsp;reported smoking a blueberry- or bubblegum-flavored synthetic cannabinoid. A unique synthetic cannabinoid, 1-((5-fluoropentyl)-1H-indol-3yl) (2,23,3,-tetramethylcyclopropyl) methanone (also called XLR-11) was found in clinical specimens and product samples [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the specific chemical agent responsible for causing renal toxicity is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H1913412#H1913412\">",
"     \"Designer drugs of abuse\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Statins and myalgias",
"    </span>",
"   </p>",
"   <p>",
"    Despite common clinical experience, higher rates of myalgia with statins, compared to placebo, have not typically been found in randomized trials designed to evaluate treatment for cardiovascular prevention. However, a six-month randomized trial in 420 healthy adults designed specifically to examine the effects of statin therapy on skeletal muscle function has found a higher incidence of myalgia in patients treated with atorvastatin 80 mg daily than with placebo (9.3 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/26\">",
"     26",
"    </a>",
"    ]. Although there have been concerns about the effects of statin therapy on exercise tolerance, no statistically-significant differences were seen in muscle strength, muscle endurance, or aerobic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin myopathy\", section on 'Myalgias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gene therapy for chylomicronemia",
"    </span>",
"   </p>",
"   <p>",
"    Type Ia hyperlipoproteinemia is an extremely rare genetic disorder. It is characterized by eruptive xanthomas, lipemia retinalis, and frequent episodes of pancreatitis. The only effective therapy has been a strict low-fat diet. A gene therapy for this condition, alipogene tiparvovec (Glybera), has been approved for use in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/27\">",
"     27",
"    </a>",
"    ], making it the first gene therapy approved for use in people. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Chylomicronemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PRIMARY CARE CARDIOVASCULAR MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Azithromycin and torsades de pointes",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients at particular risk include those with existing QT prolongation, hypokalemia, hypomagnesemia, significant bradycardia, and those receiving certain antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The warning was based on a review&nbsp;following the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/31\">",
"     31",
"    </a>",
"    ]. Clinicians should assess the risk of torsades de pointes when considering antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/28\">",
"     28",
"    </a>",
"    ]. Other macrolides and certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Duration of beta blocker after myocardial infarction",
"    </span>",
"   </p>",
"   <p>",
"    Although beta blocker (BB) therapy reduces mortality in patients with recent myocardial infarction (MI), the optimal duration of beta blocker therapy after MI is unknown. Beta blocker therapy is continued indefinitely for many patients,&nbsp;based on studies performed in the 1980s and 1990s. A 2013 observational study evaluated outcomes in&nbsp;over 5000&nbsp;patients with ST-elevation MI treated with primary percutaneous coronary intervention&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/32\">",
"     32",
"    </a>",
"    ]. Adjusted mortality rates over approximately four years&nbsp;did not differ between patients who did or did not continue&nbsp;BB therapy. However, subgroup analyses revealed that BB treatment was associated with a significantly lower mortality for high-risk patients, such as those with heart failure. We believe the available evidence supports the use of&nbsp;beta blockers in patients with MI for as long as three years. We make a weak recommendation for BB beyond three years in patients with high-risk features such as cardiogenic shock, heart failure, or chronic kidney disease.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H346544189#H346544189\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Apixaban for prevention of embolic events in atrial fibrilllation",
"    </span>",
"   </p>",
"   <p>",
"    Apixaban has been approved by the US Food and Drug Administration and the European Medicines Agency for use in patients with atrial fibrillation to reduce the risk of stroke and systemic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Approval was based on the results of the large randomized ARISTOTLE trial, which found that apixaban was non-inferior to warfarin in terms of efficacy and superior in terms of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients with atrial fibrillation who meet criteria for anticoagulation, we prefer either a factor Xa inhibitor (apixaban or rivaroxaban) or a direct thrombin inhibitor (dabigatran) to warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    Despite favorable results in the initial randomized trials, post-marketing reports have raised concerns that patients with atrial fibrillation may have a higher rate of serious bleeding with dabigatran than warfarin. In November 2012, the US Food and Drug Administration issued a statement that a review of information from insurance claims and administrative data sources suggested that the rate of bleeding with dabigatran did not appear to be higher than with warfarin in patients who were using either drug for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982501#H147982501\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Studies of anticoagulant monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PRIMARY CARE DERMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Proactive, intermittent therapy for long-term control of atopic dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    The long-term control of skin inflammation is a major challenge in the management of patients with atopic dermatitis. The 2012 European and American guidelines&nbsp;for the treatment of atopic dermatitis recommend proactive, intermittent topical&nbsp;therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. After induction of remission with continuous topical therapy, twice weekly&nbsp;application of topical&nbsp;corticosteroids&nbsp;to eczema-prone areas may prevent relapses in both adults and children with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H41442152#H41442152\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Prevention of relapses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Risk for nonmelanoma skin cancer in users of tanning beds",
"    </span>",
"   </p>",
"   <p>",
"    Tanning bed use has been associated with increased risk for cutaneous squamous cell carcinoma and basal cell carcinoma. A 2012 meta-analysis of observational studies found a 67 percent higher risk for cutaneous squamous cell carcinoma&nbsp;and a 29 percent increased risk for basal cell carcinoma among subjects with a history of any tanning bed use compared with subjects who had never used tanning beds&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UV light exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UVA radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PRIMARY CARE GASTROENTEROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PRIMARY CARE GERIATRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Discontinuing antipsychotic agents in patients with dementia",
"    </span>",
"   </p>",
"   <p>",
"    Because antipsychotic agents are associated with an increased risk of mortality in patients with dementia, it has been recommended that discontinuation of these agents should be attempted at regular intervals. One trial showed that this is not always possible. Among 180 patients with Alzheimer disease and psychosis or agitation who had initially responded to treatment with a 16 week course of risperidone, those randomly assigned to immediate drug discontinuation had an increased risk of relapse of psychosis or agitation over 16 weeks of followup (60 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/41\">",
"     41",
"    </a>",
"    ]. Those who were assigned to drug discontinuation after an additional 16 weeks of treatment also had a higher rate of relapse over the ensuing 16 weeks compared to those who continued treatment throughout (48 versus 15 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PRIMARY CARE HEMATOLOGY AND ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Duration of adjuvant tamoxifen for breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    For women taking tamoxifen as adjuvant therapy for breast cancer, the usual recommendation is for a five year course of therapy. However, the results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial found that women who took tamoxifen for ten years had a significantly lower risk of recurrence and mortality compared to women who took tamoxifen for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/42\">",
"     42",
"    </a>",
"    ]. A longer course of tamoxifen, however, also resulted in a significantly higher incidence of adverse events including endometrial cancer, pulmonary embolus, and ischemic heart disease. Overall, these results support the use of tamoxifen for ten years in women who are tolerating treatment rather than five years. This is particularly true for patients with a relatively higher risk of recurrence based on their tumor characteristics (ie, pathological node involvement, large tumor size, or high tumor grade). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Apixaban for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    The randomized, double-blind AMPLIFY-EXT study compared the efficacy and safety of apixaban with placebo in over 2000 subjects with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation and for whom there was uncertainty regarding the further continuation of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/43\">",
"     43",
"    </a>",
"    ]. Symptomatic recurrent VTE or death from VTE occurred in 8.8 and 1.7 percent of those receiving placebo or apixaban, respectively, for an overall 80 percent reduction in the risk of VTE recurrence with apixaban. Major bleeding was not increased in the group receiving apixaban. A randomized trial comparing this agent with standard-dose warfarin will help to determine the future role of apixaban for the continued treatment of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Issues to consider'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Aspirin for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    Two randomized trials, WARFASA and ASPIRE, examined the use of low-dose aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the prevention of recurrent venous thromboembolism (VTE)&nbsp;following&nbsp;6 to 18 months of anticoagulation for a&nbsp;first unprovoked episode of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. WARFASA showed a significant reduction in the rate of VTE recurrence, in contrast to&nbsp;ASPIRE, which failed&nbsp;to meet&nbsp;its primary end point of significant&nbsp;risk reduction of recurrent&nbsp;VTE.&nbsp;A prospectively planned combined analysis of both trials indicated that aspirin, compared with placebo, significantly reduced both the rate of VTE recurrence and major vascular events (a composite&nbsp;secondary endpoint of&nbsp;recurrent VTE, myocardial infarction, stroke, and cardiovascular death) by 32 and 34 percent, respectively, with no excess bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/45\">",
"     45",
"    </a>",
"    ]. After completing anticoagulant therapy following a first-time unprovoked VTE, switching to low-dose aspirin,&nbsp;is an option that may reduce the risk&nbsp; of VTE recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/46\">",
"     46",
"    </a>",
"    ].&nbsp;Direct comparison of aspirin and warafarin for the prevention of VTE was not performed&nbsp;in either&nbsp;trial and warrants further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H11015892#H11015892\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Use of aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PRIMARY CARE INFECTIOUS DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Fecal microbiota transplant for Clostridium difficile infection",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with Clostridium difficile (C. difficile)-associated diarrhea have recurrent disease after an initial course of antibiotic therapy. In an open label randomized controlled trial, 43 patients with recurrent C. difficile infection after at least one course of antibiotic therapy were randomly assigned to one of three treatment arms: duodenal infusion of donor feces preceded by an abbreviated regimen of vancomycin (vancomycin 500 mg four times daily for four days) and bowel lavage; a standard vancomycin regimen (vancomycin 500 mg four times daily for 14 days); or a standard vancomycin regimen with bowel lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/47\">",
"     47",
"    </a>",
"    ]. A single infusion of donor feces resulted in significantly higher rates of resolution of C. difficile-associated diarrhea without relapse at 10 weeks as compared with a standard vancomycin regimen with or without bowel lavage (81, 23, and 31 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link&amp;anchor=H11299943#H11299943\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\", section on 'Administration via nasogastric tube'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/48\">",
"     48",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     2012-2013 seasonal influenza vaccine effectiveness",
"    </span>",
"   </p>",
"   <p>",
"    In a case-control study of 2697 individuals with acute respiratory illness enrolled between early December 2012 and mid-January 2013, the United States Centers for Disease Control and Prevention estimated that the effectiveness of the 2012-2013 seasonal influenza vaccines in preventing medically-attended influenza infections in all age groups was 56 percent (95% CI 47-63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/49\">",
"     49",
"    </a>",
"    ]. Effectiveness against influenza A was 47 percent (95% CI 35-58 percent) and against influenza B was 67 percent (95% CI 51-78 percent). However, the age-stratified effectiveness estimate against H3N2 influenza A was only 9 percent for individuals &ge;65 years of age (compared with 46 to 50 percent for individuals from 18 to 64 years of age).",
"    <br/>",
"    <br/>",
"    Given the moderate overall effectiveness of the vaccine (and poor effectiveness against H3N2 influenza A in older adults), influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H205840196#H205840196\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Effectiveness for the 2012-2013 season'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Recurrence of erythema migrans: reinfection or relapse?",
"    </span>",
"   </p>",
"   <p>",
"    When patients develop a second episode of erythema migrans after being treated for early Lyme disease, some clinicians have been uncertain whether this represents reinfection with a different strain of Borrelia burgdorferi or relapse of the initial infection. In a study that included 22 paired (initial and second) episodes of erythema migrans, molecular typing of the B. burgdorferi gene encoding outer surface protein C (ospC) was performed using B. burgdorferi strains that were detected in cultures of skin or blood specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/50\">",
"     50",
"    </a>",
"    ]. The ospC genotype was found to be different at each initial and second episode of erythema migrans, demonstrating that repeat episodes of erythema migrans in appropriately treated patients were due to reinfection rather than relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Reinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Safety and efficacy of influenza vaccination in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for pregnant women because both mother and fetus are at increased risk of complications related to this infection, including fetal death. In addition, maternal vaccination provides passive protection to the infant. However, concerns about vaccine safety have interfered with compliance in this patient group. The safety and efficacy of vaccination of pregnant women were confirmed in a retrospective analysis of over 100,000 pregnancies during the 2009 influenza A (H1N1) pandemic in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/51\">",
"     51",
"    </a>",
"    ]. Vaccination during pregnancy substantially reduced the risk of a maternal influenza diagnosis (adjusted hazard ratio, 0.30) and was associated with a trend in reduction of fetal death. All women who are pregnant or will be pregnant during influenza season should receive the inactivated influenza vaccine, regardless of pregnancy trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795661#H5795661\">",
"     \"Influenza and pregnancy\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Meningococcal vaccination for men who have sex with men from New York City",
"    </span>",
"   </p>",
"   <p>",
"    In the fall of 2012, an outbreak of invasive meningococcal disease was detected in men who have sex with men (MSM) in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Since 2010, 14 cases have been detected, with 9 cases occurring in 2012 (as of late October). Nine of the 14 cases have been in HIV-infected men. As of late October 2012, four patients have died, three of whom were HIV-infected. Given the current outbreak, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions have put them (or will put them) in close contact with other MSM from New York City since September 1, 2012 (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H2#H2\">",
"     \"Meningococcal vaccines\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H19#H19\">",
"     \"Immunizations in HIV-infected patients\", section on 'Meningococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Egg-free influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Optaflu), produced using cultured mammalian cells, was approved in Europe for use in adults beginning in the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved for individuals &ge;18 years of age for the 2012-2013 season by the US Food and Drug Administration in November 2012&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. A second egg-free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by the FDA for adults aged 18 to 49 years. The efficacy and rates of serious adverse events seen with&nbsp;both egg-free&nbsp;vaccines were comparable to standard available influenza vaccines. For&nbsp;patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine. However, if the&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).",
"    <br/>",
"    <br/>",
"    We recommend not using&nbsp;the egg-free vaccine in patients younger than age 18, since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and the rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     PRIMARY CARE NEUROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Deep brain stimulation for early Parkinson disease",
"    </span>",
"   </p>",
"   <p>",
"    The potential benefit of deep brain stimulation (DBS) in early Parkinson disease (PD) is illustrated by the results of the EARLYSTIM trial that evaluated 251 adults (mean age 53 years) with levodopa-responsive PD, mild motor complications, and no dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/56\">",
"     56",
"    </a>",
"    ]. Compared with the medical therapy group at two years, patients in the DBS plus medical therapy&nbsp;group showed a statistically-significant and clinically-meaningful improvement in quality of life&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, the DBS group had significant improvements in motor disability, activities of daily living, levodopa-induced motor complications, and time with good mobility and no dyskinesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H92694887#H92694887\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Effectiveness in early PD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Updated guidelines for early management of acute ischemic stroke",
"    </span>",
"   </p>",
"   <p>",
"    The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association has&nbsp;published updated guidelines&nbsp;for the early management of acute ischemic stroke. One important change is that a&nbsp;number of conditions previously considered strict exclusions for the use&nbsp;of intravenous thrombolysis are now considered relative exclusions (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/58\">",
"     58",
"    </a>",
"    ]. These include minor or rapidly improving stroke symptoms, major surgery or serious trauma in the previous 14 days, gastrointestinal or urinary tract bleeding in the previous 21 days, myocardial infarction in the previous three months, and seizure at the onset of stroke with postictal neurologic impairments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H209963#H209963\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Role of eligibility criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     PRIMARY CARE PSYCHIATRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Efficacy of antidepressants for dysthymic disorder",
"    </span>",
"   </p>",
"   <p>",
"    A new study has confirmed that antidepressants are efficacious for dysthymic disorder, which is characterized by dysphoria and other depressive symptoms that last for at least two years. A meta-analysis of 20 randomized trials (nearly 3000 patients,&nbsp;most of whom were diagnosed with dysthymia)&nbsp;compared selective serotonin reuptake inhibitors (SSRIs) with placebo, tricyclic antidepressants with placebo, and SSRIs with tricyclics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/59\">",
"     59",
"    </a>",
"    ]. Treatment duration ranged from 4 to 12 weeks. Remission was greater with SSRIs or tricyclics than with placebo and was comparable for SSRIs and tricyclics. Discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H524936#H524936\">",
"     \"Initial treatment of depression in adults\", section on 'Dysthymic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Use of selective serotonin reuptake inhibitors (SSRIs) to treat pregnant patients does not appear to be associated with stillbirth or infant mortality. In an observational study of over one million pregnancies, registries from five countries were examined for information about prescriptions, maternal characteristics, pregnancy outcomes, and neonatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/60\">",
"     60",
"    </a>",
"    ]. More than 29,000 women had filled a prescription for an SSRI. After accounting for maternal age, smoking, diabetes, hypertension, and hospitalization for psychiatric illness, the risks of stillbirth and infant mortality were comparable for women who used or did not use SSRIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H8#H8\">",
"     \"Depression in pregnant women: Management\", section on 'Pregnancy complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors and bleeding",
"    </span>",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) are believed to alter platelet aggregation. A meta-analysis of 16 observational studies (n = 506,411) found that the risk of intracranial hemorrhage was elevated in patients who received SSRIs compared to controls who did not; heterogeneity across studies was small to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/61\">",
"     61",
"    </a>",
"    ]. In a separate analysis, the risk of brain hemorrhage was elevated in patients taking the combination of SSRIs and anticoagulants, compared with anticoagulants alone. However, the clinical significance of these findings is not clear. Based upon the meta-analysis, it was estimated that SSRIs may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral couples therapy for PTSD",
"    </span>",
"   </p>",
"   <p>",
"    Cognitive and behavioral psychotherapies can reduce symptoms of patients with posttraumatic stress disorder (PTSD), but there has been little research on interventions for relationship problems associated with the disorder. A randomized trial compared a manual-based, cognitive-behavioral couples therapy to a waitlist control in 40 couples that included a person with PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/63\">",
"     63",
"    </a>",
"    ]. Couples with PTSD who received the 15-session intervention experienced more improvement in intimate-relationship satisfaction and greater reduction in PTSD symptoms in the partner with the disorder, compared to the control group. This intervention shows promise, but needs further testing in larger samples of couples that have relationship difficulties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H324030410#H324030410\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Couples therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     OTHER ADULT PRIMARY CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Cardiotoxicity in women with breast cancer after radiation therapy",
"    </span>",
"   </p>",
"   <p>",
"    A&nbsp;case-control study of women treated for breast cancer with surgery and radiation therapy (RT) found that incidental radiation to the heart is associated with an increased risk&nbsp;for a significant coronary event (myocardial infarction, revascularization, or death from ischemic heart disease)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/64\">",
"     64",
"    </a>",
"    ].&nbsp;The increased risk can be seen after relatively-low doses of radiation and the presence of cardiac risk factors markedly increased the impact of radiation. Despite this, the absolute risk associated with RT appears to be small and to be outweighed by the benefits in patients for whom radiation is typically recommended.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Effect of radiation dose to the heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Ospemifene for treatment of vulvovaginal atrophy",
"    </span>",
"   </p>",
"   <p>",
"    Ospemifene is&nbsp;the first&nbsp;selective estrogen receptor modulator that is effective in treating dyspareunia resulting from menopausal vulvovaginal atrophy. It&nbsp;is an&nbsp;oral medication and&nbsp;may be helpful for women with symptomatic atrophy that is not relieved with vaginal moisturizers or lubricants and who cannot (severe arthritis, obesity, vulvodynia) or prefer not to use a vaginal product. In a&nbsp;randomized trial,&nbsp;12 weeks of ospemifene was significantly more effective than placebo in improving dyspareunia, although the benefit beyond that of placebo was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/65\">",
"     65",
"    </a>",
"    ]. Ospemifene&nbsp;has been approved by the US Food and Drug Administration, but further study is needed to compare it to vaginal estrogen therapy and to&nbsp;evaluate the risk of long-term adverse effects. It is anticipated to be available for clinical use in June 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link&amp;anchor=H2475847#H2475847\">",
"     \"Treatment of vaginal atrophy\", section on 'Selective estrogen receptor modulators'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     \"Ospemifene: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Long-term regular aspirin use and age-related macular degeneration",
"    </span>",
"   </p>",
"   <p>",
"    In&nbsp;a longitudinal&nbsp;population-based study of individuals aged 46 to 83 years at baseline, regular aspirin use was associated with a small&nbsp;increased risk of age-related macular degeneration (AMD)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/66\">",
"     66",
"    </a>",
"    ]. The estimated incidence of late AMD, comparing individuals with regular aspirin use (twice or more a week for at least three months)&nbsp;for at least ten years and non-users of aspirin, was 1.76 and 1.03 percent respectively. Aspirin use started five years before retinal&nbsp;examination was not associated with increased risk for AMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H11#H11\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Zolpidem dosing for insomnia in women",
"    </span>",
"   </p>",
"   <p>",
"    Zolpidem is a nonbenzodiazepine sedative that is widely used for treatment of insomnia and is known to cause residual daytime sedation, drowsiness, cognitive impairment, and motor incoordination in some individuals. Recent studies reviewed by the US Food and Drug Administration (FDA) suggest that 15 percent of women and 3 percent of men have next-morning zolpidem blood levels capable of impairing driving after a 10 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/67\">",
"     67",
"    </a>",
"    ]. Based on these findings, the FDA has recommended lowering the usual dose of zolpidem in women to 5 mg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H947212#H947212\">",
"     \"Treatment of insomnia\", section on 'Nonbenzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Statins and cancer outcomes",
"    </span>",
"   </p>",
"   <p>",
"    Prior observational studies have suggested that statin therapy may reduce the risk of cancer; however, these results were almost certainly due to bias and residual confounding, since meta-analyses of randomized trials have shown no comparable benefit. An observational study has now suggested improved outcomes in patients with cancer who were taking statins prior to their diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/68\">",
"     68",
"    </a>",
"    ]. This result, like those in the prior observational studies of statins and cancer risk, is most likely due to residual confounding and bias and is unconvincing until confirmed with evidence from randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/47/21242/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link&amp;anchor=H3#H3\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/1\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/2\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/3\">",
"      Estruch R, Ros E, Salas-Salvad&oacute; J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/4\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/5\">",
"      Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/6\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/7\">",
"      Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50���000 individuals. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/8\">",
"      Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/9\">",
"      Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/10\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/11\">",
"      Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/12\">",
"      Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/13\">",
"      Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/14\">",
"      Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/15\">",
"      Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012; 380:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/16\">",
"      Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/17\">",
"      Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med 2012; 156:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/18\">",
"      Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/19\">",
"      Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/20\">",
"      Rolfe A, Burton C. Reassurance After Diagnostic Testing With a Low Pretest Probability of Serious Disease: Systematic Review and Meta-analysis. JAMA Intern Med 2013; 173:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/21\">",
"      Wolf MS, King J, Jacobson K, et al. Risk of unintentional overdose with non-prescription acetaminophen products. J Gen Intern Med 2012; 27:1587.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/24\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/26\">",
"      Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bbc.co.uk/news/health-20179561 (Accessed on November 19, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/31\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/32\">",
"      Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm.",
"    </li>",
"    <li>",
"     file://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europe-prevention-stroke-and-systemic-embolism&amp;t=634890181706594412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/35\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm?source=govdelivery (Accessed on November 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/37\">",
"      Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/38\">",
"      Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/39\">",
"      Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/40\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/41\">",
"      Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/42\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/43\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/44\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/45\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/46\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/47\">",
"      van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/50\">",
"      Nadelman RB, Hanincov&aacute; K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012; 367:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/51\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/56\">",
"      Deuschl G, Sch&uuml;pbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/57\">",
"      Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/58\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/59\">",
"      von Wolff A, H&ouml;lzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013; 144:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/60\">",
"      Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/61\">",
"      Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/62\">",
"      McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/63\">",
"      Monson CM, Fredman SJ, Macdonald A, et al. Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA 2012; 308:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/64\">",
"      Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/65\">",
"      Portman DJ, Bachmann GA, Simon JA, and the Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/66\">",
"      Klein BE, Howard KP, Gangnon RE, et al. Long-term use of aspirin and age-related macular degeneration. JAMA 2012; 308:2469.",
"     </a>",
"    </li>",
"    <li>",
"     Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses Including Ambien, Ambien CR, Edluar, and Zolpimist file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm (Accessed on January 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/68\">",
"      Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/47/21242/abstract/69\">",
"      Caporaso NE. Statins and cancer-related mortality--let's work together. N Engl J Med 2012; 367:1848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8357 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21242=[""].join("\n");
var outline_f20_47_21242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mediterranean diet and prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of folate or folic acid in cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Long-term use of postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multivitamins and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vitamin D and prevention of colds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Screening colonoscopy and incidence of late stage colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rescreening for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CT colonography for colorectal cancer screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Flexible sigmoidoscopy for colorectal cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GENERAL INTERNAL MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reassurance provided by diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patient understanding of acetaminophen dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      New levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute kidney injury after synthetic cannabinoid use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Statins and myalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gene therapy for chylomicronemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PRIMARY CARE CARDIOVASCULAR MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Azithromycin and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Duration of beta blocker after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Apixaban for prevention of embolic events in atrial fibrilllation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PRIMARY CARE DERMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Proactive, intermittent therapy for long-term control of atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Risk for nonmelanoma skin cancer in users of tanning beds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PRIMARY CARE GASTROENTEROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PRIMARY CARE GERIATRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Discontinuing antipsychotic agents in patients with dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PRIMARY CARE HEMATOLOGY AND ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Duration of adjuvant tamoxifen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Apixaban for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Aspirin for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PRIMARY CARE INFECTIOUS DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Fecal microbiota transplant for Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      2012-2013 seasonal influenza vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Recurrence of erythema migrans: reinfection or relapse?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Safety and efficacy of influenza vaccination in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Meningococcal vaccination for men who have sex with men from New York City",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Egg-free influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      PRIMARY CARE NEUROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Deep brain stimulation for early Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Updated guidelines for early management of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      PRIMARY CARE PSYCHIATRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Efficacy of antidepressants for dysthymic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Selective serotonin reuptake inhibitors during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Selective serotonin reuptake inhibitors and bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Cognitive-behavioral couples therapy for PTSD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      OTHER ADULT PRIMARY CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Cardiotoxicity in women with breast cancer after radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Ospemifene for treatment of vulvovaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Long-term regular aspirin use and age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Zolpidem dosing for insomnia in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Statins and cancer outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/8357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/8357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 3\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 4\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=related_link\">",
"      Levonorgestrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=related_link\">",
"      Ospemifene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_47_21243="Positions of function selected joints";
var content_f20_47_21243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Positions of function for selected joints",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Splint",
"       </td>",
"       <td class=\"subtitle1\">",
"        Position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volar",
"       </td>",
"       <td>",
"        Neutral forearm (thumb up), wrist at 20 degrees flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulnar/radial gutter",
"       </td>",
"       <td>",
"        Neutral forearm, wrist at 20 degrees extension, MCP at 50 degrees flexion, PIP in slight flexion (10 degrees), DIP in extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thumb spica",
"       </td>",
"       <td>",
"        Forearm neutral, wrist at 25 degrees extension, allowing thumb-index finger opposition and alignment of the thumb and forearm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugar tong/posterior arm",
"       </td>",
"       <td>",
"        Elbow at 90 degrees flexion, neutral flexion, neutral wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee",
"       </td>",
"       <td>",
"        Knee fully extended if possible, up to 15 degrees of flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior ankle/ankle stirrup",
"       </td>",
"       <td>",
"        Ankle at 90 degrees",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Chudnofsky C. Splinting techniques. In: Clinical Procedures in Emergency Medicine, Roberts J, Hedges J (Eds), WB Saunders, Philadelphia, 1998. p.852.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21243=[""].join("\n");
var outline_f20_47_21243=null;
var title_f20_47_21244="Indications placental exam";
var content_f20_47_21244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential indications for examination of second and third trimester placentas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Maternal medical conditions with potential fetal effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm or postterm birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripartum fever or infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third trimester bleeding or postpartum hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe oligohydramnios or polyhydramnios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive procedures with suspected placental injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In utero fetal therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placenta previa or abruptio placentae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thick meconium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of substance abuse or exposure to toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal trauma during pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged premature rupture of membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stillbirth or neonatal death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressed neonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrops fetalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple gestation (including vanishing twin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small or large for gestational age neonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical cord abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal hematologic abnormalities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathological examination of the placenta can be omitted with normal delivery (vaginal or cesarean) of a healthy term infant from an uncomplicated pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Langston, C. Practice guideline for examination of the placenta. Archives of Pathology &amp; Laboratory Medicine 1997; 121:449. Khong, TY. From delivery suite to laboratory: optimizing returns from placental examination in medico-legal defense. Aust N Z J Obstet Gynaecol 1997; 37:1. Kaplan, C, Lowell, DM, Salafia, C. College of American Pathologists Conference XIX on the Examination of the Placenta: report of the Working Group on the Definition of Structural Changes Associated with Abnormal Function in the Maternal/Fetal/Placental Unit in the Second and Third Trimesters. Arch Pathol Lab Med 1991; 115:709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21244=[""].join("\n");
var outline_f20_47_21244=null;
var title_f20_47_21245="Approach HBV summary";
var content_f20_47_21245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for treatment of chronic hepatitis B in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       HBeAg",
"      </td>",
"      <td class=\"subtitle1\">",
"       HBV DNA (PCR)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ALT",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment strategy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       +",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &gt;20,000 IU/mL",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &le;2x ULN",
"      </td>",
"      <td>",
"       Low efficacy with current treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Observe; consider treatment when ALT becomes elevated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider biopsy in persons &gt;40 years, ALT persistently high normal-2x ULN, or with family history of HCC.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider treatment if HBV DNA &gt;20,000 IU/mL and biopsy shows moderate/severe inflammation or significant fibrosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"11\">",
"       +",
"      </td>",
"      <td colspan=\"1\" rowspan=\"11\">",
"       &gt;20,000 IU/mL",
"      </td>",
"      <td colspan=\"1\" rowspan=\"11\">",
"       &gt;2x ULN",
"      </td>",
"      <td>",
"       Observe for 3-6 months and treat if no spontaneous HBeAg loss.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider liver biopsy prior to treatment if compensated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immediate treatment if icteric or clinical decompensation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IFN&alpha;/peg IFN&alpha;, LAM, ADV, ETV or LdT may be used as initial therapy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LAM and LdT not preferred due to high rate of drug resistance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       End-point of treatment - Seroconversion from HBeAg to anti-HBe.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Duration of therapy:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       IFN&alpha;: 16 weeks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Peg IFN&alpha;: 48 weeks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       LAM/ADV/ETV/LdT: minimum 1 year, continue for at least 6 months after HBeAg seroconversion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IFN&alpha; non-responders / contraindications to IFN&alpha; &rarr; ADV/ETV.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       -",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       &gt;20,000 IU/mL",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       &gt;2x ULN",
"      </td>",
"      <td>",
"       IFN&alpha;/peg IFN&alpha;, LAM, ADV, ETV or LdT may be used as initial therapy, LAM and LdT not preferred due to high rate of drug resistance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       End-point of treatment - not defined.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Duration of therapy:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       IFN&alpha;/peg IFN&alpha;: 1 year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       LAM/ADV/ETV/LdT: &gt;1 year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IFN-&alpha; nonresponders / contraindications to IFN-&alpha; &rarr; ADV/ETV.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       &gt;2,000 IU/mL",
"      </td>",
"      <td>",
"       1-&gt;2x ULN",
"      </td>",
"      <td>",
"       Consider liver biopsy and treat if liver biopsy shows moderate/severe necroinflammation or significant fibrosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       &le;2,000 IU/mL",
"      </td>",
"      <td>",
"       &le;ULN",
"      </td>",
"      <td>",
"       Observe, treat if HBV DNA or ALT becomes higher.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       +/-",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Detectable",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Cirrhosis",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Compensated:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HBV DNA &gt;2,000 IU/mL - Treat, LAM/ADV/ETV/LdT may be used as initial therapy. LAM and LdT not preferred due to high rate of drug resistance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HBV DNA &lt;2,000 IU/mL - Consider treatment if ALT elevated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Decompensated:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Coordinate treatment with transplant center, LAM (or LdT) + ADV or ETV preferred. Refer for liver transplant.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       +/-",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Undetectable",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Cirrhosis",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Compensated:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Observe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Decompensated:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Refer for liver transplant",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; ULN: upper limit of normal; IFN&alpha;: interferon alpha; peg IFN&alpha;: pegylated IFN alpha; LAM: Lamivudine; ADV: Adefovir; ETV: Entecavir; LdT: Telbivudine.",
"    </div>",
"    <div class=\"reference\">",
"     Lok, AS, McMahon, BJ. AASLD Practice Guideines: Chronic hepatitis B. Hepatology 2007; 45:507.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21245=[""].join("\n");
var outline_f20_47_21245=null;
var title_f20_47_21246="Contents: Neurologic disease";
var content_f20_47_21246=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurologic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurologic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Delirium",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/55/1913\">",
"           Cholinesterase inhibitors in the treatment of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/55/1914\">",
"           Clinical features and diagnosis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27162\">",
"           Clinical manifestations and diagnosis of Alzheimer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/41/34455\">",
"           Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37786\">",
"           Etiology, clinical manifestations, and diagnosis of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28057\">",
"           Evaluation of cognitive impairment and dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/20/12618\">",
"           Frontotemporal dementia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/408\">",
"           Frontotemporal dementia: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/36/15946\">",
"           Parkinson disease dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41369\">",
"           Prevention of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21031\">",
"           Prognosis and treatment of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36202\">",
"           Risk factors for dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4552\">",
"           Safety and societal issues related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10104\">",
"           Treatment and prevention of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27402\">",
"           Treatment of behavioral symptoms related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33865\">",
"           Treatment of dementia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/41/12951\">",
"           Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40841\">",
"           Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23303\">",
"           The mental status examination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/2/5161\">",
"           Treatment of orthostatic and postprandial hypotension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/6/17512\">",
"           Treatment of seizures and epilepsy in the elderly patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parkinson disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/13/14554\">",
"           Clinical manifestations of Parkinson disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/35/2618\">",
"           Antiplatelet therapy for secondary prevention of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31688\">",
"           Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/11/10426\">",
"           Initial evaluation and management of transient ischemic attack and minor stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AC3DE11020-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_47_21246=[""].join("\n");
var outline_f20_47_21246=null;
var title_f20_47_21247="Towel stretch PI";
var content_f20_47_21247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Towel stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold a 3-foot-long towel in both hands behind your back in the horizontal position. Then use your good arm to pull the towel so that your affected arm moves toward your lower back. You can also hold the towel at an angle (as shown) to do this exercise. Repeat this stretch 10 to 20 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_47_21247=[""].join("\n");
var outline_f20_47_21247=null;
